Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS -- Tokens.com Reports Financial Results for Q2 2024
TORONTO, May 09, 2024--(BUSINESS WIRE)--Tokens.com Corp. (TSX-V: COIN)(Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a technology company focused on building AI-integrated humanoid robots, is pleased to report its financial results for three and six months ended March 31, 2023 ("Q2-2024"). All dollar figures are in United States dollars ("USD"), unless otherwise stated.
Q2-2024 Financial and Operating Highlights
NEWS -- Tokens.com Reports Financial Results for Q2 2024
TORONTO, May 09, 2024--(BUSINESS WIRE)--Tokens.com Corp. (TSX-V: COIN)(Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a technology company focused on building AI-integrated humanoid robots, is pleased to report its financial results for three and six months ended March 31, 2023 ("Q2-2024"). All dollar figures are in United States dollars ("USD"), unless otherwise stated.
Q2-2024 Financial and Operating Highlights
NEWS -- Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
Company acquired all assets for the synergistic CNSide cerebrospinal fluid diagnostic portfolio
Company will summarize topline data from the FORESEE clinical trial planned for presentation at the
SNO/ASCO Meeting in August 2024
Management call scheduled for Thursday, May 9th, 2024 at 8:30 AM ET
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces it will host an investor call on Thursday, May 9th, 2024 at 8:30 AM ET to discuss the strategic acquisition of the CNSide cerebrospinal fluid (CSF) testing assets.
During the call, President and Chief Executive Officer Dr. Marc H. Hedrick will discuss the rationale for the CNSide acquisition and an overview of the assets acquired. In addition, he will also provide key updates since the September 2023 sublicense of CNSide, including topline data from the FORESEE trial, subsequent publications, interim milestones, the Company's business plan to leverage the acquired assets and planned future milestones.
Conference Call and Webcast
Thursday, May 9, 2024 @ 8:30 AM ET
Dial-in Link: https://register.vevent.com/register/BIdc75c8a5a88c41c683b270235002d285
Webcast: https://edge.media-server.com/mmc/p/nor9kmxs
Participants may also pre-register any time before the call through the dial-in-link. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company’s website under the “For Investors” section. The webcast will be available on the Company’s website for 90 days following the live call.
About CNSide Test
CNSide is a laboratory developed test (LDT) based on proprietary quantitative tumor cell capture and detection method, paired with assays to identify actionable molecular treatment targets. Given the genetic changes that can occur as metastatic cancer spreads to the CNS, the evaluation of cerebrospinal fluid with CNSide provides a unique opportunity to identify biomarkers in patients with metastatic carcinoma or melanoma to help guide physicians in therapy selection. In addition, the quantitative tumor cell count assay can be used in a serial fashion to monitor the response to therapy more effectively than other current methods.
About FORESEE clinical trial
The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM). Standard of Care methods to diagnose or assess the treatment response of LM (Clinical Evaluation, MRI and Cytology) have limited sensitivity and specificity. This creates challenges for physicians to manage LM or determine the best course of treatment. The goal of the FORESEE Study is to evaluate the performance of CNSide in monitoring the LM's response to treatment and to assess the impact of CNSide on treatment decisions made by Physicians.
About Leptomeningeal Metastases (LM)
LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary brain tumors, or hematological malignancies have this LM complication potential with breast cancer as the most common cancer linked to LM, with 3-5% of breast cancer patients developing LM. Additionally, lung cancer, GI cancers and melanoma can also spread to the CSF and result in LM. LM occurs in approximately 5% of people with cancer and is usually terminal with 1-year and 2-year survival of just 7% and 3%, respectively. The incidence of LM is on the rise, partly because cancer patients are living longer and partly because many standard chemotherapies cannot reach sufficient concentrations in the spinal fluid to kill the tumor cells, yet there are no FDA-approved therapies specifically for LM patients, who often succumb to this complication within weeks to several months, if untreated.
About Rhenium (186Re) obisbemeda
Rhenium (186Re) obisbemeda is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. Rhenium (186Re) obisbemeda has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. Rhenium (186Re) obisbemeda is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT).
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.
Cautionary Statement Regarding Forward-Looking Statements
This presentation contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of rhenium (186Re) obisbemeda including the ability of rhenium (186Re) obisbemeda to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM and ReSPECT-PBC and increase of ten o, clinical trials; possible negative effects of rhenium (186Re) obisbemeda; the continued evaluation of rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms, and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Charles Y. Huang, MBA
Director of Capital Markets and Investor Relations
Office: (202)-209-5751 | Direct (301)-728-7222
mailto://chuang@plustherapeutics.com
NEWS -- Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study
Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq®) combination expands existing pancreatic cancer program
First patient expected to be enrolled in Q2 2024
SAN DIEGO and CALGARY, AB, May 9, 2024 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals. This cohort will evaluate pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq®) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC). It is supported by a US$5M Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer. The chemotherapy regimens of mFOLFIRINOX or gemcitabine + nab-paclitaxel are the two most common standards of care for pancreatic cancer.1 Oncolytics has already reported data with the combination of gemcitabine and nab-paclitaxel (link to the PR, link to the poster) that surpassed historical outcomes.2-5 Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
"Oncolytics is pleased to announce receipt of regulatory clearance to initiate the mFOLFIRINOX cohort in patients with newly diagnosed metastatic PDAC. We appreciate the opportunity to collaborate with PanCAN, Roche, and AIO on this cohort, which is expected to initiate enrollment in the second quarter," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community. We are also grateful for PanCAN's Therapeutic Accelerator Award, which is enabling the evaluation of this combination therapy."
"The Therapeutic Accelerator Award program has been an important part of PanCAN's approach to advancing innovative treatments for pancreatic cancer. We incorporated input from leading scientists and clinicians in the field of pancreatic cancer to select Oncolytics as a recipient of this award," said Anna Berkenblit, MD, MMSc, Chief Scientific and Medical Officer at PanCAN. "Increasing patient access to clinical trials is vital to developing improved treatment options, so we are pleased that Oncolytics has received regulatory clearance for the pelareorep/mFOLFIRINOX combination and is poised to enroll the first patient in this cohort. We hope that the results from this study lead to improved outcomes for patients with pancreatic cancer."
Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg and primary investigator of the GOBLET trial, commented, "Oncolytics has taken a very strategic approach to the development of pelareorep in pancreatic cancer by focusing its clinical studies on combinations with the most widely used treatment regimens. My experience to date with the GOBLET study, including the positive metastatic PDAC and encouraging anal cancer data reported last year, makes me enthusiastic to initiate enrollment in the mFOLFIRINOX cohort."
"We previously reported very encouraging results in pancreatic cancer patients for the combination of pelareorep, gemcitabine/nab-paclitaxel, and atezolizumab, and we plan to begin a registration-enabling study of this regimen later this year. The new pelareorep/mFOLFIRINOX cohort offers the opportunity to expand pelareorep's role in pancreatic cancer. If the mFOLFIRINOX combination shows a compelling efficacy signal, this therapeutic approach could also be advanced to a registration-enabling study, providing two opportunities for pelareorep-based treatment to benefit pancreatic cancer patients," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics. "In addition, translational research studies planned for this cohort will help to further elucidate pelareorep's mechanism of action, including its ability to shape the tumor microenvironment (TME). Notably, we will evaluate the correlation between tumor responses and the expansion of tumor-infiltrating lymphocytes (TILs) in the blood, an effect that was observed in earlier pancreatic cancer studies. We look forward to initiating enrollment into the mFOLFIRINOX/pelareorep study cohort in the second quarter of this year."
References
NEWS -- Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
SAN DIEGO and CALGARY, AB, May 8, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference, which is taking place May 14-15, 2024 at the InterContinental New York Barclay in New York, NY. Additional details on the fireside chat can be found below.
Date: Wednesday, May 15, 2024
Time: 10:30 a.m. ET
Location: InterContinental New York Barclay Grand Ballroom I, 2nd Floor
Webcast Link: Available by clicking here
Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, contact your RBC representative or email mailto://jpatton@oncolytics.ca.
A live webcast of the Company's presentation will also be available on the Investor Relations page of Oncolytics' website (LINK) and will be archived until August 13, 2024.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: https://www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Contacts:
Company Contact
Jon Patton
Director of IR & Communication
mailto://jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
mailto://tim@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/1762876/Oncolytics_Biotech_New_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/oncolytics-biotech-to-participate-in-a-fireside-chat-at-the-2024-rbc-capital-markets-global-healthcare-conference-302139526.html
SOURCE Oncolytics Biotech® Inc.
NEWS -- Scorpius Holdings Appoints New VP of Business Development Shari Udoff-McDonald
Biopharma industry veteran joins Scorpius’ leadership team
DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the appointment of Shari Udoff-McDonald as VP of Business Development. She brings more than 25 years of experience in biopharma business development and management.
Prior to joining Scorpius, Ms. Udoff-McDonald spent 17 years at BioReliance Corporation, part of MilliporeSigma. She was most recently Head of Commercial, North America, East with interim oversight of half of the European market. Her role included commercial oversight of biologics, vaccines, cell and gene therapies, ADCs, and mRNA GMP testing services for sponsors and CDMOs.
Joe Payne, Scorpius’ President and COO, said, “Shari has the unique combination of experience in the field, at the account-level, and in leadership roles. This wide breadth of business development experience will help Scorpius continue to grow its customer base. I’m confident that Shari will have an immediate, positive impact on our current and future clients.”
Ms. Udoff-McDonald will oversee the business development, marketing, and proposals teams, which are addressing the strong demand for flexible mammalian and microbial biomanufacturing services. Scorpius’ facility in San Antonio, Texas, has available capacity for mammalian and microbial programs, which are supported by on-site process and analytical development services.
“I’m thrilled to join Scorpius BioManufacturing at this key growth stage,” said Ms. Udoff-McDonald. “Scorpius is committed to being a transparent, flexible, and responsive CDMO partner. I am impressed by their technical and scientific capabilities and am even more impressed by the passion and enthusiasm displayed by the team. I look forward to working with current and future clients to bring their large molecule drugs to market.”
Ms. Udoff-McDonald and the Scorpius business development team will be at the BIO International Convention in San Diego on June 3-6. To schedule a meeting, visit https://www.scorpiusbiologics.com/contact-us.
About Scorpius Holdings
Scorpius BioManufacturing Inc. is a wholly owned subsidiary of Scorpius Holdings Inc., an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit https://www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as contributions to be made by Shari Udoff-McDonald including her business development experience helping Scorpius continuing to grow its customer base and working with current and future clients to bring their large molecule drugs to market. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of Shari Udoff-McDonald to make contributions to Scorpius, the Company’s ability to regain compliance with the NYSE American continued listing standards, expand its large molecule biomanufacturing CDMO services and continue to grow revenue; the Company’s financing needs, its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO, and other factors described in the Company’s most recent annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media & Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://ir@scorpiusbiologics.com
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
CARLSBAD, Calif., May 06, 2024--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month visual acuity results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), were presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit. The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute. The presentation, "OpRegen® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial," was presented by David Telander, MD, PhD, Retinal Consultants Medical Group, on behalf of Roche and Genentech, a member of the Roche Group.
RG6501 (OpRegen) is a suspension of human allogeneic retinal pigment epithelial (RPE) cells currently in development for the treatment of GA secondary to AMD. OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function. It is being developed under an exclusive worldwide collaboration between Lineage, Roche, and Genentech, a member of the Roche Group, and is currently being evaluated in a Phase 2a clinical study in patients with GA secondary to AMD (ClinicalTrials.gov Identifier: NCT05626114).
"The products approved recently for the treatment of GA secondary to AMD have not demonstrated a compelling functional benefit, so there remains a need for treatments that can positively affect patient vision," stated Brian M. Culley, Lineage CEO. "We are encouraged by the apparent durability of visual performance being achieved by patients in this study, notably in the 5 patients who received a thorough coverage of OpRegen cells across the majority of their atrophic areas and who had experienced a cessation or reversal of their areas of atrophy, evidenced by outer retinal structural improvements on optical coherence tomography (OCT). Dry AMD has traditionally been considered to be an irreversible and progressively degenerative disease leading to vision loss. However, these data suggest that OpRegen RPE cells may provide a one-time treatment which could slow or even reverse this damage by way of direct support to the patients’ remaining retinal cells, including those near or within atrophic areas. We look forward to additional, future clinical data updates on the OpRegen program from our partners, Roche and Genentech."
2024 Retinal Cell & Gene Therapy Innovation Summit Highlights
NEWS -- Tokens.com to Release its Financial Results for Q2-2024 on May 9, 2024
TORONTO, May 06, 2024--(BUSINESS WIRE)--Tokens.com Corp. ("Tokens.com" or the "Company") (TSX-V: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF), a technology investment company focused on humanoid robotics and relationship-based AI, is pleased to share that it will release its financial results for the three and six months ended March 31, 2024 ("Q2-2024") on May 9, 2024.
An investor webinar hosted by CEO Andrew Kiguel on Zoom has been scheduled to discuss the Company’s Q2 2024 financial results starting at 4:00 pm ET on May 9th, 2024.
Date: May 9th, 2024
Time: 4:00 p.m. ET
Zoom Webinar Registration:
https://us06web.zoom.us/webinar/register/WN__H9ESWIYQUSUbhOVTir7sQ
To join the webinar, register using the link provided above. Upon registration a Zoom link will be emailed to the registered email address. The webinar will be available via computer, tablet, and smartphone devices. In addition, a dial-in phone number will be provided in the email upon registration. Callers dialing in using a telephone will automatically be placed in a listen only mode. The question period will not be available to dial-in callers.
About Tokens.com
Tokens.com is a technology company focused on building ultra-realistic humanoid robotics and companionship based AI. Tokens.com also owns 15.3% of StoryFire Inc., an inventory of cryptocurrencies and a collection of top ranked crypto related domain names.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, Facebook, Instagram and YouTube.
Forward-Looking Statements
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "shall", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements in this news release include statements relating to the expected closing date of the Transaction and the projected impact of the acquisition of Simulacra on the Company’s business, financial conditions and results.
Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. Important factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements include, among others: (a) the risk that the closing conditions for completion of the Transaction, including TSXV approval, are not satisfied; (b) risks relating to general economic, market and business conditions; and (c) unforeseen delays in the timelines for any of the transactions or events described in this press release.
We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act") or any states securities laws and may not be offered or sold within the United states or to US Persons (as defined in Regulation S under the US Securities Act) unless registered under the US Securities Act and applicable state securities laws or an exemption from such registration is available.
Neither TSXV nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240506953460/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Telephone: 647-578-7490
NEWS -- Tokens.com to Release its Financial Results for Q2-2024 on May 9, 2024
TORONTO, May 06, 2024--(BUSINESS WIRE)--Tokens.com Corp. ("Tokens.com" or the "Company") (TSX-V: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF), a technology investment company focused on humanoid robotics and relationship-based AI, is pleased to share that it will release its financial results for the three and six months ended March 31, 2024 ("Q2-2024") on May 9, 2024.
An investor webinar hosted by CEO Andrew Kiguel on Zoom has been scheduled to discuss the Company’s Q2 2024 financial results starting at 4:00 pm ET on May 9th, 2024.
Date: May 9th, 2024
Time: 4:00 p.m. ET
Zoom Webinar Registration:
https://us06web.zoom.us/webinar/register/WN__H9ESWIYQUSUbhOVTir7sQ
To join the webinar, register using the link provided above. Upon registration a Zoom link will be emailed to the registered email address. The webinar will be available via computer, tablet, and smartphone devices. In addition, a dial-in phone number will be provided in the email upon registration. Callers dialing in using a telephone will automatically be placed in a listen only mode. The question period will not be available to dial-in callers.
About Tokens.com
Tokens.com is a technology company focused on building ultra-realistic humanoid robotics and companionship based AI. Tokens.com also owns 15.3% of StoryFire Inc., an inventory of cryptocurrencies and a collection of top ranked crypto related domain names.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, Facebook, Instagram and YouTube.
Forward-Looking Statements
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "shall", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements in this news release include statements relating to the expected closing date of the Transaction and the projected impact of the acquisition of Simulacra on the Company’s business, financial conditions and results.
Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. Important factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements include, among others: (a) the risk that the closing conditions for completion of the Transaction, including TSXV approval, are not satisfied; (b) risks relating to general economic, market and business conditions; and (c) unforeseen delays in the timelines for any of the transactions or events described in this press release.
We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act") or any states securities laws and may not be offered or sold within the United states or to US Persons (as defined in Regulation S under the US Securities Act) unless registered under the US Securities Act and applicable state securities laws or an exemption from such registration is available.
Neither TSXV nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240506953460/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Telephone: 647-578-7490
NEWS -- Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
CARLSBAD, Calif., May 02, 2024--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update.
Interested parties may access the conference call on May 9th, 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through May 15th, 2024, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 1330332.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or "off-the-shelf," cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage’s neuroscience focused pipeline currently includes: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visit https://www.lineagecell.com or follow the company on X/Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502738426/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://ir@lineagecell.com)
(442) 287-8963
LifeSci Advisors
Daniel Ferry
(mailto://daniel@lifesciadvisors.com)
(617) 430-7576
Russo Partners – Media Relations
Nic Johnson or David Schull
(mailto://Nic.johnson@russopartnersllc.com)
(mailto://David.schull@russopartnersllc.com)
(212) 845-4242
NEWS -- Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has allowed patent application 17/232,393, titled “Halogenated Xanthene Composition and Method for Treating Hematologic Cancers” (formerly “Composition and Method for Oral Treatment of Leukemia”). The application covers the use of Provectus’s pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceutical ingredient for the single agent or combination therapy treatment of pediatric and adult leukemias. Earlier this year, Provectus announced notices of allowance and award for U.S. patents of RBS in virology, pediatric solid tumor cancers, and vaccines.
Innovate Calgary, the innovation company of the University of Calgary in Alberta, Canada, is a co-assignee and Aru Narendran, MD, PhD, Professor of Pediatrics, Oncology, Biochemistry and Molecular Biology and Physiology and Pharmacology at the University’s Cumming School of Medicine is a co-inventor on all four patent awards.
Dominic Rodrigues, President and Vice Chairman of Provectus’s Board of Directors said, “As we remain focused on advancing intratumoral administered cancer immunotherapy PV-10 towards initial drug approval for metastatic pancreatic cancer, our evidence-based confidence in the potential and possibilities of oral administration of rose bengal sodium for the treatment of disease continues to grow.”
About Provectus
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium.
Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.
Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, https://ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:
The Company’s Annual Report on Form 10-K for the period ended December 31, 2023.
#####
Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
NEWS -- StoryFire, a Tokens.com Investment Company, Launches Token
TORONTO, May 01, 2024--(BUSINESS WIRE)--Tokens.com Corp. ("Tokens.com" or the "Company") (TSX-V: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF), a technology investment company, is pleased to announce that StoryFire Inc, 15.3% owned by Tokens.com, has successfully launched its BLAZE cryptocurrency token.
StoryFire successfully launched its BLAZE token on April 25th. The Blaze token is listed and trades on several exchanges including PancakeSwap and MEXC.
The BLAZE token has seen a strong initial response in the market, trading up over 55% from the initial listing price. As part of Tokens.com's sale of Metaverse Group (MVG) and Hulk Labs to StoryFire in March 2024, Tokens.com was provided US$500,000 of BLAZE tokens that hold a current value of approximately US$1.5 million. More information on the BLAZE token can be found here.
"As Tokens.com expands into the AI and robotics sectors, we are pleased to see our legacy investments succeeding. We congratulate our partners at StoryFire on the successful launch of their Blaze token. We support their endeavors and are excited to see the growth happening quickly on our investment in their business," said Andrew Kiguel, CEO of Tokens.com.
About Tokens.com
Tokens.com is a technology company focused on building ultra-realistic humanoid robotics and companionship based AI. Tokens.com also owns 15.3% of StoryFire Inc., an inventory of cryptocurrencies and a collection of top ranked crypto related domain names.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, Facebook, Instagram and YouTube.
About StoryFire
StoryFire is a private online social entertainment and gaming platform that empowers users to create and engage with immersive narratives. With a rapidly growing user base of 2.5 million, StoryFire offers a vibrant and creative community for storytellers and enthusiasts. StoryFire users create social posts akin to Twitter, gain a following and earn an in-app currency known as Blaze. StoryFire is a privately owned entity.
For more information visit https://storyfire.com/.
Forward-Looking Statements
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "shall", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements in this news release include statements relating to the expected closing date of the Transaction and the projected impact of the acquisition of Simulacra on the Company’s business, financial conditions and results.
Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. Important factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements include, among others: (a) the risk that the closing conditions for completion of the Transaction, including TSXV approval, are not satisfied; (b) risks relating to general economic, market and business conditions; and (c) unforeseen delays in the timelines for any of the transactions or events described in this press release.
We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act") or any states securities laws and may not be offered or sold within the United states or to US Persons (as defined in Regulation S under the US Securities Act) unless registered under the US Securities Act and applicable state securities laws or an exemption from such registration is available.
Neither TSXV nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501312733/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Telephone: 647-578-7490
NEWS -- StoryFire, a Tokens.com Investment Company, Launches Token
TORONTO, May 01, 2024--(BUSINESS WIRE)--Tokens.com Corp. ("Tokens.com" or the "Company") (TSX-V: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF), a technology investment company, is pleased to announce that StoryFire Inc, 15.3% owned by Tokens.com, has successfully launched its BLAZE cryptocurrency token.
StoryFire successfully launched its BLAZE token on April 25th. The Blaze token is listed and trades on several exchanges including PancakeSwap and MEXC.
The BLAZE token has seen a strong initial response in the market, trading up over 55% from the initial listing price. As part of Tokens.com's sale of Metaverse Group (MVG) and Hulk Labs to StoryFire in March 2024, Tokens.com was provided US$500,000 of BLAZE tokens that hold a current value of approximately US$1.5 million. More information on the BLAZE token can be found here.
"As Tokens.com expands into the AI and robotics sectors, we are pleased to see our legacy investments succeeding. We congratulate our partners at StoryFire on the successful launch of their Blaze token. We support their endeavors and are excited to see the growth happening quickly on our investment in their business," said Andrew Kiguel, CEO of Tokens.com.
About Tokens.com
Tokens.com is a technology company focused on building ultra-realistic humanoid robotics and companionship based AI. Tokens.com also owns 15.3% of StoryFire Inc., an inventory of cryptocurrencies and a collection of top ranked crypto related domain names.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, Facebook, Instagram and YouTube.
About StoryFire
StoryFire is a private online social entertainment and gaming platform that empowers users to create and engage with immersive narratives. With a rapidly growing user base of 2.5 million, StoryFire offers a vibrant and creative community for storytellers and enthusiasts. StoryFire users create social posts akin to Twitter, gain a following and earn an in-app currency known as Blaze. StoryFire is a privately owned entity.
For more information visit https://storyfire.com/.
Forward-Looking Statements
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "shall", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements in this news release include statements relating to the expected closing date of the Transaction and the projected impact of the acquisition of Simulacra on the Company’s business, financial conditions and results.
Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. Important factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements include, among others: (a) the risk that the closing conditions for completion of the Transaction, including TSXV approval, are not satisfied; (b) risks relating to general economic, market and business conditions; and (c) unforeseen delays in the timelines for any of the transactions or events described in this press release.
We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act") or any states securities laws and may not be offered or sold within the United states or to US Persons (as defined in Regulation S under the US Securities Act) unless registered under the US Securities Act and applicable state securities laws or an exemption from such registration is available.
Neither TSXV nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501312733/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Telephone: 647-578-7490
NEWS -- Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
CNW Group
Conference call and webcast to take place on Thursday, May 9, 2024, at 4:30 p.m. ET
SAN DIEGO and CALGARY, AB, April 30, 2024 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter 2024.
Conference Call & Webcast
Date: Thursday, May 9, 2024
Time: 4:30 p.m. ET
Dial In – North American Toll-Free: (800) 836-8184
Dial In – International: (289) 819-1350
RapidConnect: to join the conference call without operator assistance, please click here
Conference ID (if needed): 77797
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 660-6345 (North America) or (289) 819-1450 (International) and using replay code: 77797#.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: https://www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Company Contact
Jon Patton
Director of IR & Communication
mailto://jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
mailto://tim@lifesciadvisors.com
Logo - https://mma.prnewswire.com/media/1762876/Oncolytics_Biotech_New_Logo.jpg
View original content to download multimedia: https://www.prnewswire.com/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and-recent-operational-highlights-302131344.html
SOURCE Oncolytics Biotech® Inc.
NEWS -- Lineage Announces Changes to Board of Directors
CARLSBAD, Calif., April 29, 2024 -- (BUSINESS WIRE) -- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) is saddened to report the passing of its long-serving Chairman of the Board of Directors, Mr. Alfred D. Kingsley, and offers its deepest condolences to Mr. Kingsley’s family for their loss. Mr. Kingsley served as Chairman of the Company’s Board of Directors since July 2009, and was a significant contributor in the evolution of the Company into a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs.
Effective as of April 27, 2024, Michael H. Mulroy, J.D., has been appointed by the Board of Directors to serve as the Chairman of the Board of Directors.
"We are incredibly saddened by Al’s passing and offer our thoughts, prayers, and support to the entire Kingsley family during this difficult time," stated Michael H. Mulroy. "Al was exceptionally committed to Lineage and its shareholders, and brought great innovation, leadership, and dedication to others to his work. Al was not only a key contributor to the company from the beginning, but also set an example for all of us through his generosity to the community. It has been a privilege to serve alongside him on the Board and we look forward to continuing to build upon his legacy."
Mr. Mulroy’s background includes experience as a biotech and biopharma corporate executive, and as a corporate attorney and investment banker. He has served as a member of the Board of Directors since 2014 and serves as Chair of the Compensation Committee and as a member of the Audit Committee and the Financial Strategy Committee. Mr. Mulroy brings extensive expertise across a number of operational and functional areas, including corporate finance and development, and clinical and strategic operations. He previously served as Chief Executive Officer and a member of the board of directors of Asterias Biotherapeutics, Inc. Prior to joining Asterias, Mr. Mulroy served as a Senior Advisor to CamberView Partners, LLC (now part of PJT Partners Inc.), which assists companies in connection with investor engagement and complex corporate governance issues. Prior to its sale in 2014, Mr. Mulroy served as Executive Vice President, Strategic Affairs and General Counsel of Questcor Pharmaceuticals, Inc. (QCOR), where he also previously served as Chief Financial Officer. Mr. Mulroy earned his J.D. degree from the University of California, Los Angeles and his B.A. degree in economics from the University of Chicago.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or "off-the-shelf," cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage’s neuroscience focused pipeline currently includes: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visit https://www.lineagecell.com or follow the company on X/Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429858960/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://ir@lineagecell.com)
(442) 287-8963
LifeSci Advisors
Daniel Ferry
(mailto://daniel@lifesciadvisors.com)
(617) 430-7576
Russo Partners – Media Relations
Nic Johnson or David Schull
(mailto://Nic.johnson@russopartnersllc.com)
(mailto://David.schull@russopartnersllc.com)
(212) 845-4242
NEWS -- Scorpius Holdings Provides 2023 Year-End Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023
DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius” or “the Company”), an integrated contract development and manufacturing organization providing state-of-the-art large molecule contract development and manufacturing organization (“CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2023.
Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, “We are executing our plan to augment sales and drive revenue, as evidenced by the $4.8 million of revenue from continuing operations that we reported in the fourth quarter of 2023. This represents a 570% increase from the third quarter of 2023, and a 226% increase compared to revenue for the first nine months of the year. To date, Scorpius’s successful business development efforts have resulted in the recording of more than $20 million of contract bookings. We believe our bookings, coupled with the strong interest in our microbial and mammalian capabilities and promising pipeline of new opportunities, positions us well for significant growth in 2024 and beyond.”
"As the large molecule drug substance CDMO market is projected to grow from $10 billion in 2023 to $21 billion by 20301, there is a substantial need for enhanced industry capacity. With our scalable business model and the rising demand for our large molecule CDMO services, we believe that we are well-positioned to capture a meaningful share of this market. Moreover, we expect Scorpius’ growth to accelerate in 2024 and remain optimistic about becoming cash flow positive by early 2025. With the completion of our facility and divestiture of our research and non-core assets, we substantially reduced our operating expenses in the fourth quarter of 2023. As a result, we believe the future for Scorpius could not be brighter as our 60,000+ sq. ft. campus provides us sufficient capacity to grow our business with minimal additional capex requirements, which we believe is the key to maximizing profits and returns for our shareholders,” concluded Mr. Wolf.
2023 Financial Results
NEWS -- Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
ROCKVILLE, Md., April 25, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on the strength of the science and its relevance, VIRAGE - the Phase 2b randomized, open-label, placebo-controlled, multicenter clinical trial of systemically administered VCN-01 in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) - has been accepted for presentation as a trial-in-progress poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL, from May 31-June 4.
ASCO Presentation Details
NEWS -- Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the acceptance of two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from May 31 – June 4, 2024, in Chicago, Illinois. Details on the abstracts and poster presentation are shown below.
Title: Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.
Presentation Type: Poster
Abstract Number: TPS4203
Session Title: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date and Time: June 1, 2024, 1:30 – 4:30 p.m. CT
Title: Pelareorep driven blood TIL expansion in patients with pancreatic, breast and colon cancer.
Presentation Type: Online abstract
Abstract Number: e14625
Abstracts will be published on the ASCO Annual Meeting website at 5:00 p.m. ET on May 23, 2024.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: https://www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com
View original content: https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-upcoming-presentations-at-the-american-society-of-clinical-oncology-annual-meeting-302127249.html
SOURCE Oncolytics Biotech® Inc.
Stockholm syndrome describes the psychological condition of a victim who identifies with and empathizes with their captor or abuser and their goals.
NEWS -- Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma
Phase 1 trial in collaboration with Sant Joan de Déu-Barcelona Children’s Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee
Safety and clinical outcomes support the therapeutic potential of VCN-01 in retinoblastoma and emphasize VCN-01’s potential for use in diverse cancer indications
ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced positive topline data from the investigator sponsored Phase 1 trial conducted by collaborators at Sant Joan de Déu-Barcelona Children’s Hospital (SJD). The Phase 1 trial was designed to evaluate the safety and tolerability of two intravitreal injections of Theriva’s investigational oncolytic adenovirus VCN-01 in patients (n=9) with intraocular retinoblastoma that is refractory to chemotherapy or radiotherapy, and for whom enucleation was the only recommended treatment.
“Results from the investigator sponsored trial further validate VCN-01’s unique mechanism of action and therapeutic potential to improve patient outcomes in otherwise refractory cancers,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “We look forward to building on the encouraging safety profile and antitumor activity, which further supports and informs the design of our proposed Phase 2 clinical trial. The Monitoring Committee determined that the trial results were positive, and therefore, Theriva will receive an exclusive, worldwide license, and related patents from SJD for the treatment of pediatric patients with advanced retinoblastoma. The positive completion of this trial is an important step in refining our clinical strategy for VCN-01 as an adjunct to chemotherapy to address the high unmet need in this underserved indication.”
Key Takeaways: Patients received two intravitreal injections of VCN-01, 14 days apart, at a dose of either 2 x 109 vp/eye (n=1) or 2 x 1010 vp/eye (n=8). The data for 9 evaluable patients were reviewed by the study Monitoring Committee who agreed that the trial had a positive outcome:
NEWS -- Scorpius Holdings Announces Receipt of Filing Delinquency Notification
Reaffirms commitment to regaining compliance with the NYSE American continued listing standards
DURHAM, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), received an official notice of noncompliance (the “NYSE American Notice”) from NYSE Regulation stating that the Company is not in compliance with NYSE American LLC (“NYSE American” or the “Exchange”) continued listing standards (the “Filing Delinquency Notification”) under the timely filing criteria included in Section 1007 of the NYSE American Company Guide (the "Company Guide") due to the failure to timely file the Company’s Form 10-K for the period ended December 31, 2023 (the “Delinquent Report”) by the filing due date of April 16, 2024 (the “Filing Delinquency”).
As previously reported in the Company’s Notification of Late Filing on Form 12b-25 filed with the SEC on April 1, 2024, the Company was unable to file its Annual Report on Form 10-K for the year ended December 31, 2023, within the prescribed period because of delays experienced by the Company in preparing its consolidated financial statements. The delays relate to recent finance staff turnover of those directly involved in preparing the Delinquent Report, and the need for additional time to complete the calculation of revenue recognition for certain contracts for the year ended December 31, 2023.
Jeff Wolf, CEO of Scorpius, stated, “We regret the delay in filing our Form 10-K, due in part to substantive changes within our organization. We expect to file our year-end financial results in short order. Most importantly, we remain committed to maintaining the highest standards of financial reporting and corporate governance.”
The Company is now subject to the procedures and requirements set forth in Section 1007 of the NYSE American Company Guide. Within five days of the date of the Filing Delinquency Notification, the Company was required to (a) contact the Exchange to discuss the status of the Delinquent Report and (b) issue a press release disclosing the occurrence of the Filing Delinquency, the reason for the Filing Delinquency and, if known, the anticipated date such Filing Delinquency will be cured via the filing or refiling of the applicable report, as the case may be.
During the six-month period from the date of the Filing Delinquency (the "Initial Cure Period"), the NYSE will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured. If the Company fails to cure the Filing Delinquency within the Initial Cure Period, the Exchange may, in the Exchange’s sole discretion, allow the Company’s securities to be traded for up to an additional six-month period (the "Additional Cure Period") depending on the Company’s specific circumstances. If the Exchange determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the NYSE American Company Guide. If the Exchange determines that an Additional Cure Period of up to six months is appropriate and the Company fails to file its Delinquent Report and any subsequent delayed filings by the end of that period, suspension and delisting procedures will generally commence. An issuer is not eligible to follow the procedures outlined in Section 1009 with respect to these criteria.
Notwithstanding the foregoing, however, the Exchange may in its sole discretion decide (i) not to afford an issuer any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the Exchange believes, in the NYSE’s sole discretion, that continued listing and trading of an issuer's securities on the Exchange is inadvisable or unwarranted in accordance with Sections 1001-1006 hereof.
The Company intends to regain compliance with the NYSE American continued listing standards. There can be no assurance that the Company will ultimately regain compliance with all applicable NYSE American continued listing standards.
Scorpius Holdings, Inc.
Scorpius Holdings Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit https://www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as the Company’s expectation to expand the scope of the agreement to include Phase 1 clinical manufacturing, the Company’s ability to file its Annual Report on Form 10-K during the Initial Cure Period and its ability to regain compliance with the NYSE American continued listing standards Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to regain compliance with the NYSE American continued listing standards, expand its large molecule biomanufacturing CDMO services and continue to grow revenue; the Company’s financing needs, its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO, and other factors described in the Company’s most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://ir@scorpiusbiologics.com
NEWS -- Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft
The observed synergy emphasizes VCN-01’s potential in diverse chemotherapy combinations for improved efficacy in the treatment of pancreatic cancer
ROCKVILLE, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the presentation of preclinical data demonstrating enhanced anti-tumor effects in human pancreatic cancer xenograft-bearing mice treated with lead product candidate VCN-01 and liposomal irinotecan. These data support the potential synergy of VCN-01 and first-line pancreatic cancer chemotherapy regimens, and will be featured in a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) 27th Annual Meeting, being held both virtually and in Baltimore from May 7-11, 2024.
“The data featured at the upcoming ASGCT meeting build on recent findings that suggest the combination of VCN-01 and topoisomerase I inhibitors, such as liposomal irinotecan, may provide a synergistic antitumor effect to improve therapeutic outcomes across indications,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “We look forward to leveraging these findings and evaluating the combination of VCN-01 with additional first-line pancreatic cancer chemotherapy regimens, including NALIRIFOX and FOLFIRINOX. In parallel, we continue to progress our on-going VIRAGE Phase 2b trial evaluating VCN-01 in combination with gemcitabine/nab-paclitaxel to treat metastatic pancreatic ductal adenocarcinoma (PDAC). Together, these important steps bring us one step closer to building a portfolio of potentially improved therapeutic combinations for PDAC patients with high unmet medical needs.”
Key takeaways include:
Overview: The combination of VCN-01 + topoisomerase I (topo1) inhibitors, such as liposomal irinotecan, has a tolerable toxicity profile and may improve efficacy in the treatment of human pancreatic cancer.
NEWS -- Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
Plus now has $23 million in active awards support for the Company’s targeted radiotherapeutic pipeline
Funding for pediatric brain cancer treatment is expected to begin in Q3 2024, pending contract finalization
AUSTIN, Texas, April 22, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP). The award is expected to commence in Q3 2024 and will support the planned expansion of the Company’s clinical trial for pediatric brain cancer.
“This recent award further extends our current cash runway in the second half of 2025, while supporting the 2024 expansion of our clinical development activities,” said Marc H. Hedrick, M.D., President & CEO of Plus Therapeutics. “In 2023, the Company applied for approximately $7 million in grant funding, and we plan to file for more than $10 million in funding in 2024.”
About the DoD Grant Program
The DoD Peer Reviewed Cancer Research Program (PRCRP) Advancing Cancer Care through Clinical Trials Award will be utilized to fund a Phase 1 dose escalation trial to address the FY23 PRCRP Topic Area of Pediatric Brain Tumors. This study will investigate a novel therapeutic, Rhenium (186Re) Obisbemeda (186RNL), delivered by Convection Enhanced Delivery (CED), for the treatment of supratentorial recurrent, refractory, or progressive pediatric high-grade glioma (HGG) and ependymoma. It is expected to begin enrollment in the second half of 2024.
About Rhenium (186Re) obisbemeda
Rhenium (186Re) obisbemeda is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. Rhenium (186Re) obisbemeda has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. Rhenium (186Re) obisbemeda is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT).
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.
Cautionary Statement Regarding Forward-Looking Statements
This presentation contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of rhenium (186Re) obisbemeda including the ability of rhenium (186Re) obisbemeda to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM and ReSPECT-PBC and increase of ten o, clinical trials; possible negative effects of rhenium (186Re) obisbemeda; the continued evaluation of rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms, and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Charles Huang
Director, Capital Markets and Investor Relations
(202) 209 5751
mailto://chuang@plustherapeutics.com
NEWS -- FuelPositive Announces Strategic Focus on Manitoba, Expanding Network and New Partnerships
WATERLOO, Ontario, April 18, 2024 (GLOBE NEWSWIRE) -- FuelPositive Corporation, a leading Green Ammonia Company (TSX.V: NHHH) (OTCQB: NHHHF) (the "Company" or "FuelPositive") is delighted to provide an update on the Company’s strategic commitment to Manitoba, as FuelPositive continues to expand its network and forge new partnerships.
“Manitoba is the future of global agriculture,” said Ian Clifford, FuelPositive's Co-Founder and CEO. “The combination of climate, freshwater access and Canada’s globally encompassing trade agreements means that Manitoba is becoming the global hub of agriculture and agri-tech. There is nowhere better in Canada to be in the business of farming.”
This update is the first in a series aimed at reinforcing FuelPositive’s dedication to the growth and development of Manitoba, Canada. With a clear focus on expanding its network, FuelPositive is ready to establish new partnerships that resonate with its mission, values, and most importantly, the needs of the Company’s primary customers – farmers.
FuelPositive is grateful for the invaluable advice and support provided by its esteemed advisors, whose guidance has been empowering the Company’s team to pursue opportunities that not only benefit FuelPositive but also contribute to the flourishing communities of Manitoba.
As part of this initiative, FuelPositive is thrilled to unveil upcoming partnerships that will bolster its presence and deepen its impact throughout Manitoba and beyond. These collaborations underscore FuelPositive’s unwavering commitment to sustainable growth and the creation of meaningful opportunities for local stakeholders.
“FuelPositive is dedicated to fostering positive transformation across Canada, with an initial emphasis on Manitoba. Our strategic concentration on this region signifies not only our profound faith in its potential but also our unwavering resolve to ignite progress," affirmed Luna Clifford, FuelPositive's Co-Founder, and Chief Impact Officer.
New Manitoba Farmer-Partner and FuelPositive Advisor: Chad Berry
FuelPositive is delighted to announce the appointment of its new Farmer-Advisor, Chad Berry. Mr. Berry partners in and operates the 12,000-acre Under the Hill Farms in Glenboro, Manitoba. Mr. Berry, a third-generation potato grower, has extensive experience in regenerative and sustainable farming practices.
Mr. Berry was introduced to FuelPositive by Dr. Mario Tenuta, Senior Industrial Research Chair in 4R Nutrient Management and Professor of Soil Ecology at the University of Manitoba. Dr. Tenuta researches the relationship between nutrient management and greenhouse gas emissions. As a FuelPositive’s advisor, Dr. Tenuta supports the Company's efforts toward the mitigation/elimination of on-farm nitrogen emissions and helps connect its team with Manitoba-based farmers and stakeholders. Dr. Tenuta is a world-renowned scientist who is well-connected to Manitoba and its farming communities.
“FuelPositive not only gives farmers more options for access to cost and supply stability, their strong initiatives in supporting farmers reducing their carbon footprint of food production, places Manitoba growers at a competitive advantage in a changing market looking to net zero models of farm operations," stated Dr. Tenuta. "Along with the FuelPositive team, I visited Chad's progressive potato and farm operation. Mr. Berry and his family were welcoming, and the visit was productive and insightful. Particularly, we explored how Green Ammonia production can be integrated with fertigation of crops."
As a leader in innovative agricultural practices, Chad Berry has adopted many regenerative practices, including reduced tillage by direct seeding into stubble, limiting soil disruption, mitigating wind-caused soil erosion, improving water infiltration, solar panels/energy installation and being more efficient with fuel-saving through reduced fuel use. Under-the-Hill Farms is also being considered for one of FuelPositive's pilot systems to showcase the FP1500A, which includes the Aqueous Green Ammonia add-on module, currently being developed by the Company.
"We are thrilled to welcome Chad to the FuelPositive team," stated Luna Clifford. "Chad's deep understanding of the Manitoba agricultural landscape, coupled with his passion for sustainability and new technology, aligns with our vision for the future of farming. His expertise will help drive FuelPositive's mission forward."
"Any time we can find a new tool in the toolbox and utilize it to be more sustainable for future generations by controlling input costs and supply, we consider it," stated Chad Berry. "FuelPositive's technology would be an Ag-tech investment that can help create that control for us and countless other farmers," concluded Mr. Berry.
Mr. Berry is one of the farmers representing the Canadian Potato Sustainability Alliance. He is notable for his participation in developing programs as part of the Greenhouse Gas Evaluation Team.
Mr. Berry is also President of the Keystone Potato Producers Association in the Potato Marketing Association of North America. The Keystone Association represents approximately 85% of Manitoba's potato growers and significantly supports research to expand the potato industry.
Mr. Berry, alongside Dr. Tenuta, advises the Company on adapting its system output to farmers' needs, such as using Aqueous Green Ammonia as a UAN replacement in fertigation in potato farming. Berry's firsthand insights will be essential in guiding the Company as it adapts its systems to meet the unique and diverse needs of plant-based farmers in Canada.
"Chad Berry's invaluable insights are guiding us in customizing our solutions to address the unique fertilizer and fuel challenges faced by Canadian potato farmers. We eagerly anticipate collaborating closely with Chad to advance our mission of promoting sustainable agriculture practices," Ian Clifford stated.
"As we press forward towards a more sustainable future, we are thankful for the increasing support from farmers. Together, we are steadfast in our commitment to driving positive change in the agricultural industry and empowering farmers to flourish amidst a rapidly changing landscape," concluded Luna Clifford.
Media update:
FuelPositive is excited to announce a groundbreaking new initiative: expanding our creative team with the addition of talented photographers and graphic designers. The completion and shipment of our first On-site Green ammonia system mark a pivotal moment in our dedication to enriching our online presence and elevating the brand experience for our valued stakeholders.
With these skilled professionals joining our ranks, we are poised to revolutionize our digital platform, offering an immersive showcase of our team, cutting-edge systems, and state-of-the-art facilities. We strive to effectively showcase the cutting-edge innovation that defines FuelPositive through dynamic imagery and updated information.
This initiative underscores our unwavering commitment to transparent communication with our stakeholders. By providing a window into our achievements and milestones, we invite our audience to share in our journey and celebrate our collective success.
"It has been a privilege collaborating with the team at FuelPositive over the past few months. Capturing their progress has been an incredible experience, highlighting the dedication and hard work they've poured into their endeavours. I look forward to continuing to document FuelPositive's journey as they embark on this next phase of growth," stated Alexia Cina, one of FuelPositive's photographers.
"Alexia has meticulously documented our recent Ministry of Agriculture visits, the farmers' visit on April 10, and is currently capturing the shipping of our inaugural system from Waterloo to its arrival in Manitoba," stated Luna Clifford. "Her keen eye for detail has beautifully showcased this pivotal moment in our Company's history. We are thrilled to share more updates, including today's pictures of the shipping process."
About FuelPositive Corporation
FuelPositive is a Canadian technology company dedicated to delivering commercially feasible and sustainable clean technology solutions that follow a circular approach, ensuring the entire lifecycle of our products is environmentally friendly. This includes an on-farm/onsite, containerized Green Ammonia (NH3) production system that effectively eliminates carbon emissions during the production process.
By focusing on technologies that are clean, sustainable, economically advantageous and realizable, the Company aims to help mitigate climate change, addressing unsustainable agricultural practices through innovative technology and practical solutions that can be implemented now. The FuelPositive on-farm/onsite, containerized Green Ammonia production system is designed to produce pure, anhydrous ammonia for multiple applications, including fertilizer for farming, fuel for grain drying and internal combustion engines, a practical alternative for fuel cells and a solution for grid storage. Green Ammonia is also considered a key enabler of the hydrogen economy.
FuelPositive systems are designed to provide for Green Ammonia production on-farm/onsite, where and when needed. This eliminates wildly fluctuating supply chains and offers end-users clean fertilizer, energy and Green Ammonia supply security while eliminating carbon emissions from the production process. The first customers will be farmers. Farmers use 80% of the traditional grey ammonia produced today as fertilizer.
See pre-sale details here: https://fuelpositive.com/pre-sales/.
FuelPositive Corporation is based in Waterloo (Canada) and trades on the TSX Venture Exchange under the symbol NHHH and in the USA on the OTCQB under the symbol NHHHF.
For further information, please contact:
Ian Clifford
Co-Founder Chief Executive Officer and Board Chair
mailto://Ian@fuelpositive.com
Tel: 416.535.8395
https://www.fuelpositive.com
Logan Ross
Senior Vice President, Communications & Campaigns
Counsel Public Affairs, Inc.
mailto://lross@counselpa.com
Tel: 204.720.3662
https://www.counselpa.com
Investor Relations United States & International:
RB Milestone Group (RBMG)
mailto://fuelpositive@rbmilestone.com
Investor Relations Canada:
Transcend Capital Inc.
mailto://et@transcendcapitalinc.com
Cautionary Statement
Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) that are based on expectations, estimates and projections as of the date of this news release. The information in this release about future plans and objectives of the Company, including with respect to further testing and implementation of the FP300 system, are forward-looking statements.
These forward-looking statements are based on assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect.
Many of these uncertainties and contingencies can directly or indirectly affect and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Forward-looking information is provided for the purpose of providing information about management’s expectations and plans relating to the future. The Company disclaims any intention or obligation to update or revise any forward-looking information or to explain any material difference between subsequent actual events and such forward-looking information, except to the extent required by applicable law.
NEWS -- Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers
KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancers.
Titled Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10, a copy of the University of Calgary’s journal article is available here: https://www.mdpi.com/2072-6694/16/8/1520.
This work has been part of research conducted by Aru Narendran, M.D., Ph.D., professor in the departments of Pediatrics, Oncology, and Biochemistry & Molecular Biology, and members of the Narendran Lab at the University of Calgary’s Cumming School of Medicine in Calgary, Alberta, Canada.
The Narendran Lab provided preclinical proof-of-concept data supporting the efficacy of Provectus’s rose bengal in a panel of adult solid tumors. The Lab identified that the Company’s rose bengal downregulated WNK1 and Wnt signaling. In mice, the Narendran Lab also confirmed the clinical utility of Provectus’s rose bengal by intratumoral (aka intralesional) administration and demonstrated potential utility by oral administration.
Dominic Rodrigues, the Company’s President and Vice Chairman of its Board of Directors stated, “Provectus is focused on initiating an FDA-cleared, lead clinical development program for intratumoral cancer immunotherapy PV-10 to treat hepatic metastatic pancreatic cancer, and pursuing a path to an initial drug approval for PV-10. The Company previously demonstrated its systemic response and systemic immune signaling and activation in clinical settings for metastatic liver cancers.”
Mr. Rodrigues added, “Building on PV-10’s clinical safety, efficacy, and immunotherapeutic profile, the Narendran Lab’s preclinical data suggest that Provectus’s pharmaceutical-grade rose bengal delivered by oral administration may have the potential to treat a larger pool of solid tumor cancers.”
About Provectus
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium.
Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.
Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, https://ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: The information provided in this press release may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission, including those described in Item 1A of:
The Company’s Annual Report on Form 10-K for the period ended December 31, 2023.
#####
Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
NEWS -- Tokens.com Closes Acquisition of Simulacra Corporation
TORONTO, April 18, 2024--(BUSINESS WIRE)--Tokens.com Corp. ("Tokens.com" or the "Company") (TSX-V: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF), a technology investment company, has successfully closed its acquisition of all the issued and outstanding shares of Simulacra Corporation ("Simulacra").
Simulacra owns and operates three subsidiaries focused on the integration of artificial intelligence ("AI") and high quality, humanoid robots that improve the human experience through connection, learning and play. All amounts herein are expressed in U.S. dollars, unless otherwise stated.
Since 1997, Simulacra has been producing realistic silicone humanoid figures. In the last four years, Simulacra has generated revenues of $15.6 million (CAD$21.1 million) and Gross Profit of $12.1 million (CAD$16.3 million). The Transaction (as defined below) is expected to be revenue accretive to Tokens.com shareholders. More information on Simulacra can be found on their website here and an investor deck can be found here.
Utilizing its intellectual property and design expertise, Simulacra is positioned to expand beyond its current sectors of entertainment and marketing into other markets that benefit from high quality, natural looking, humanoid robots, and personalized AI systems, such as healthcare (elderly care, mental health) and education. Through their customized AI and realistic robots, Simulacra is positioned to be a leader in the newly emerging AI companionship market.
On the completion of the Transaction, Matt McMullen, the founder and CEO of Simulacra, will join Tokens.com as President and as a director. Mr. McMullen and Shrike Holdings Inc., another Simulacra shareholder, will also become new Insiders (as defined in policies of the TSX Venture Exchange (the "TSXV") of the Company.
"The completion of this Transaction marks another milestone in our journey at Tokens.com," said Andrew Kiguel, CEO of Tokens.com. "This acquisition diversifies our assets and business base. Going forward, we will be less reliant on the performance of crypto prices. This aligns with our vision of providing shareholders exposure to disruptive technologies that are defining the future and propelling us forward into new realms of innovation and possibility".
Transaction Consideration and Other Details
Tokens.com will issue 75 million common shares to Simulacra shareholders in consideration for the acquisition (the "Transaction"). This will equate to approximately 38% of outstanding common shares of Tokens.com on the completion of the transaction. The common shares issued to Simulacra shareholders will be escrowed for 12 months and then gradually released between months 12 to 24 following the closing date. Tokens.com will also grant an aggregate of 7,500,000 stock options in exchange for the cancellation of 567,101 stock options of Simulacra. The Tokens.com stock options will be granted at an exercise price of $0.15 per stock option and will expire on the 10th anniversary of the closing date of the Transaction.
In addition, Simulacra shareholders will have the opportunity to earn an additional 10 million Tokens.com shares if they achieve revenue targets of $8 million within any 12 month period during the first 24 months following the completion of the Transaction and an additional 10 million Tokens.com shares if they achieve revenues of $10 million with any 12 month period between months 24 and 48 following the closing date.
Subsequent to the closing of the Transaction, it is expected that Tokens.com will have a total of 195,995,592 common shares outstanding and 1,469,950 in-the-money options outstanding. The Company also has 1,902,540 deferred stock units (held 100% by directors on the board) and 9,777,289 warrants outstanding with an exercise price of CAD$1.15 that expire in November 2024.
Each of Simulacra and its shareholders are arm’s length parties to the Company. No broker, agent or finder’s fee is payable in connection with the Transaction.
Simulacra Subsidiaries
(i) Realbotix
Realbotix builds customized ultra-realistic robots that are AI-enabled. These robots look, talk, and move like humans. Invented for use in entertainment, companionship, healthcare, and education markets. For an example of Realbotix’s products, please see the link here.
(ii) Anthropomorphic Figure Dynamics ("AFD")
AFD is a unique division that caters to government and healthcare projects that require highly realistic humanoids. This would include previous contracts with the US military and John Hopkins hospital.
(iii) Abyss Creations
Abyss Creations builds companionship-based humanoid figures that have the ability to be integrated with AI features.
About Tokens.com
Tokens.com is a technology company focused on building ultra-realistic humanoid robotics and companionship based AI. Tokens.com also owns 15.3% of StoryFire Inc., an inventory of cryptocurrencies and a collection of top ranked crypto related domain names.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, Facebook, Instagram and YouTube.
Forward-Looking Statements
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "shall", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements in this news release include statements relating to the expected closing date of the Transaction and the projected impact of the acquisition of Simulacra on the Company’s business, financial conditions and results.
Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. Important factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements include, among others: (a) the risk that the closing conditions for completion of the Transaction, including TSXV approval, are not satisfied; (b) risks relating to general economic, market and business conditions; and (c) unforeseen delays in the timelines for any of the transactions or events described in this press release.
We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act") or any states securities laws and may not be offered or sold within the United states or to US Persons (as defined in Regulation S under the US Securities Act) unless registered under the US Securities Act and applicable state securities laws or an exemption from such registration is available.
Neither TSXV nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418830174/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Telephone: 647-578-7490
NEWS -- Tokens.com Closes Acquisition of Simulacra Corporation
TORONTO, April 18, 2024--(BUSINESS WIRE)--Tokens.com Corp. ("Tokens.com" or the "Company") (TSX-V: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF), a technology investment company, has successfully closed its acquisition of all the issued and outstanding shares of Simulacra Corporation ("Simulacra").
Simulacra owns and operates three subsidiaries focused on the integration of artificial intelligence ("AI") and high quality, humanoid robots that improve the human experience through connection, learning and play. All amounts herein are expressed in U.S. dollars, unless otherwise stated.
Since 1997, Simulacra has been producing realistic silicone humanoid figures. In the last four years, Simulacra has generated revenues of $15.6 million (CAD$21.1 million) and Gross Profit of $12.1 million (CAD$16.3 million). The Transaction (as defined below) is expected to be revenue accretive to Tokens.com shareholders. More information on Simulacra can be found on their website here and an investor deck can be found here.
Utilizing its intellectual property and design expertise, Simulacra is positioned to expand beyond its current sectors of entertainment and marketing into other markets that benefit from high quality, natural looking, humanoid robots, and personalized AI systems, such as healthcare (elderly care, mental health) and education. Through their customized AI and realistic robots, Simulacra is positioned to be a leader in the newly emerging AI companionship market.
On the completion of the Transaction, Matt McMullen, the founder and CEO of Simulacra, will join Tokens.com as President and as a director. Mr. McMullen and Shrike Holdings Inc., another Simulacra shareholder, will also become new Insiders (as defined in policies of the TSX Venture Exchange (the "TSXV") of the Company.
"The completion of this Transaction marks another milestone in our journey at Tokens.com," said Andrew Kiguel, CEO of Tokens.com. "This acquisition diversifies our assets and business base. Going forward, we will be less reliant on the performance of crypto prices. This aligns with our vision of providing shareholders exposure to disruptive technologies that are defining the future and propelling us forward into new realms of innovation and possibility".
Transaction Consideration and Other Details
Tokens.com will issue 75 million common shares to Simulacra shareholders in consideration for the acquisition (the "Transaction"). This will equate to approximately 38% of outstanding common shares of Tokens.com on the completion of the transaction. The common shares issued to Simulacra shareholders will be escrowed for 12 months and then gradually released between months 12 to 24 following the closing date. Tokens.com will also grant an aggregate of 7,500,000 stock options in exchange for the cancellation of 567,101 stock options of Simulacra. The Tokens.com stock options will be granted at an exercise price of $0.15 per stock option and will expire on the 10th anniversary of the closing date of the Transaction.
In addition, Simulacra shareholders will have the opportunity to earn an additional 10 million Tokens.com shares if they achieve revenue targets of $8 million within any 12 month period during the first 24 months following the completion of the Transaction and an additional 10 million Tokens.com shares if they achieve revenues of $10 million with any 12 month period between months 24 and 48 following the closing date.
Subsequent to the closing of the Transaction, it is expected that Tokens.com will have a total of 195,995,592 common shares outstanding and 1,469,950 in-the-money options outstanding. The Company also has 1,902,540 deferred stock units (held 100% by directors on the board) and 9,777,289 warrants outstanding with an exercise price of CAD$1.15 that expire in November 2024.
Each of Simulacra and its shareholders are arm’s length parties to the Company. No broker, agent or finder’s fee is payable in connection with the Transaction.
Simulacra Subsidiaries
(i) Realbotix
Realbotix builds customized ultra-realistic robots that are AI-enabled. These robots look, talk, and move like humans. Invented for use in entertainment, companionship, healthcare, and education markets. For an example of Realbotix’s products, please see the link here.
(ii) Anthropomorphic Figure Dynamics ("AFD")
AFD is a unique division that caters to government and healthcare projects that require highly realistic humanoids. This would include previous contracts with the US military and John Hopkins hospital.
(iii) Abyss Creations
Abyss Creations builds companionship-based humanoid figures that have the ability to be integrated with AI features.
About Tokens.com
Tokens.com is a technology company focused on building ultra-realistic humanoid robotics and companionship based AI. Tokens.com also owns 15.3% of StoryFire Inc., an inventory of cryptocurrencies and a collection of top ranked crypto related domain names.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, Facebook, Instagram and YouTube.
Forward-Looking Statements
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "shall", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements in this news release include statements relating to the expected closing date of the Transaction and the projected impact of the acquisition of Simulacra on the Company’s business, financial conditions and results.
Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. Important factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements include, among others: (a) the risk that the closing conditions for completion of the Transaction, including TSXV approval, are not satisfied; (b) risks relating to general economic, market and business conditions; and (c) unforeseen delays in the timelines for any of the transactions or events described in this press release.
We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act") or any states securities laws and may not be offered or sold within the United states or to US Persons (as defined in Regulation S under the US Securities Act) unless registered under the US Securities Act and applicable state securities laws or an exemption from such registration is available.
Neither TSXV nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418830174/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Telephone: 647-578-7490
NEWS -- Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced additions to its executive leadership team, reflecting Provectus's dedication to enhancing shareholder value. The Company’s Board of Directors (the “Board”) has appointed Ed Pershing as Chief Executive Officer (“CEO”) and Dominic Rodrigues as President.
New Executive Appointments
Mr. Pershing has served as Board chairman since 2018 and was a Board observer and chairman of the Company’s Strategic Advisory Board from 2017 to 2018. Mr. Rodrigues has served as Provectus’s chief operating consultant in 2024 and vice chairman since 2018 and was chairman from 2017 to 2018. They will continue to serve in their respective Board roles.
Mr. Pershing co-founded Pershing Yoakley & Associates (“PYA”) in 1983 and was its President and CEO until his retirement from the firm in 2019. PYA is a top 20 healthcare consulting and top 100 accounting firm in the U.S., growing from a three-employee office to more than 350 employees and four affiliate companies serving more than 3,500 clients in all 50 states. Mr. Pershing’s healthcare experience and expertise include turnaround and performance improvement initiatives, long-range planning studies, development of numerous hospital and medical office projects, restructuring of healthcare organizations, liaison between boards of directors and management, mergers, acquisitions, divestitures, and leasing arrangements. He also served as an expert witness on healthcare industry matters and represented healthcare organizations before federal and state regulatory agencies.
Mr. Rodrigues worked in management consulting and corporate development in science and technology-driven industries prior to Provectus. He also was a finance professor at the University of Nevada, Las Vegas, a venture capitalist at defense contractor SAIC, a currency derivatives trader at Bank of Montreal, and a project manager and engineer at Jacques Whitford. Mr. Rodrigues holds business, economics, engineering, and public policy degrees from The Wharton School, the London School of Economics, MIT, and the University of Toronto.
Mr. Pershing stated, “Since 2017, Mr. Rodrigues has managed clinical development, research collaborations, key vendors, and other Provectus activities in all biotechnology business functions, supported our finance and accounting team, and been a contributing member of the board of directors.”
Mr. Pershing added, “Mr. Rodrigues has secured existing molecular biochemical, medical scientific, and manufacturing process knowledge from Provectus’s former founders and contributed to the creation of new insights in these areas. His efforts ensure that all corporate understandings can be efficiently conveyed to new team members and development partners in the future.”
Mr. Pershing concluded, “Mr. Rodrigues and I first met as fellow shareholders at the 2010 annual meeting of the American Society of Clinical Oncology where Provectus clinical data were being presented. We have long shared a supreme confidence in the singular distinctiveness of the Company’s rose bengal sodium molecule. In asking him to join me in 2017 to save Provectus and its truly unique science, Mr. Rodrigues unequivocally embraced my vision of pushing the molecule to achieve its true potential as an expansive therapeutic platform capable of transforming the way the healthcare industry treats disease. With our team of dedicated, perseverant executives, employees, consultants, and clinical and research collaborators, we will continue to execute on our mission to develop and commercialize innovative, broad-spectrum, immunotherapy medicines that are safe, effective, accessible, and affordable, and that can revolutionize the healthcare industry as we know it.”
Commitment to Shareholder Value Creation
Provectus remains committed to delivering long-term value to its shareholders. On the Company’s First Quarter 2024 Conference Call, Provectus outlined its key areas of focus for 2024:
NEWS -- FuelPositive Announces Completion of Factory Acceptance Testing and Shipping of First Commercial System
Highlights:
WATERLOO, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- FuelPositive Corporation, a leading Green Ammonia Company (TSX.V: NHHH) (OTCQB: NHHHF) (the "Company" or "FuelPositive") is pleased to announce that the Factory Acceptance Testing (FAT) was successfully completed by FuelPositive’s farmer-partner and advisor, Curtis Hiebert, from Sperling, Manitoba and shipment of the world’s first FuelPositive FP300 system has commenced.
Curtis Hiebert took time out of his busy spring season schedule to visit the team at FuelPositive's new small-batch manufacturing facility in Waterloo, Ontario, to complete the FAT and mandatory safety training for the first FP300, which will be delivered on-farm this week. Tracy and Curtis Hiebert were selected as recipient of the World’s first FuelPositive’s demonstration pilot for the FuelPositive's on-farm Containerized Green Ammonia system.
"The Hiebert Factory Acceptance Testing was completed successfully, and our team is thrilled and incredibly proud of this collaborative achievement," stated Nelson Leite, FuelPositive's Chief Technology Officer and Board Member. "The system was demonstrated at our Waterloo facility installed the way it will be installed in Manitoba. FuelPositive’s team will be in Sperling, Manitoba, this week to receive the first FP300 and begin its commissioning."
"The Factory Acceptance is a huge milestone for us and FuelPositive. Seeing the system installed and operating makes this whole project that much more real. We are very much looking forward to its arrival on the farm in the coming days. It is amazing for us to be first in the world. We are very proud to be the first farm," said Curtis Hiebert. "Thinking ahead and setting a solid future for our family is the most important thing for us," added Hiebert.
Several farmers, potential customers, and investors attended on April 10 to meet with FuelPositive's team to learn more about the Company's current technology and future projects. This provided a first hand opportunity for farmers to witness the FP300 system in action and gain insights into its capabilities.
Manitoba-based multi-generational precision agriculture grain farmers Daniel and Scott Kroeker and Corey Park, General Manager of Rutherford Farms, which is one of the top seed producers in Canada and a near "net-zero" farming enterprise joined the event.
"The tour and training were helpful and informative for Scott and me. We are very excited to have the first system on Curtis' farm! We're also investors in FuelPositive. It was great to meet the team that is putting this all together. As farmers, leaving the land better than we found it and creating a solid legacy for our kids is a big motivation. FuelPositive understands how important this is to many farmers," said Daniel Kroeker, co-owner/operator.
"Having FuelPositive systems on our farms will significantly reduce our emissions footprint and could quickly push us into a "net-zero" reality," added Corey Park. "The launch of FuelPositive's Canadian technology in Manitoba has the potential to be a game-changer for farmers worldwide."
"This day marks a pivotal moment for the Company, resulting from months of dedicated teamwork and expertise. The transformative impact of what unfolds next at the Hiebert’s farm will set a new standard, revolutionizing farming practices worldwide," concluded Ian Clifford, Co-Founder, CEO, and Board Chair of FuelPositive.
The first On-Farm FP300 system ships on April 15, 2024:
As a result of the major FAT milestone, FuelPositive has remained on schedule and has begun shipping the First FP300 system today. FuelPositive expects it will take up to a week for all the components to arrive on-farm in Manitoba and will continue to provide photos and updates as on-farm delivery is completed.
"We're incredibly excited about what today means for our dedicated company and determined team. We're beyond proud. Our technology has the potential to make a difference in farmers' quality of life and for the environment," stated Luna Clifford, FuelPositive Co-Founder and CIO. "We set out to build a company mindful of its impact on the world and its people, and we are succeeding. Our technology aims to empower farmers, by providing them with easy and affordable access to fertilizer and fuel and bringing much-needed stability. It is also about raising awareness amongst Canadians about global food security and the solutions available today."
About FuelPositive Corporation
FuelPositive is a Canadian technology company dedicated to delivering commercially feasible and sustainable clean technology solutions that follow a circular approach, ensuring the entire lifecycle of our products is environmentally friendly. This includes an on-farm/onsite, containerized Green Ammonia (NH3) production system that effectively eliminates carbon emissions during the production process.
By focusing on technologies that are clean, sustainable, economically advantageous and realizable, the Company aims to help mitigate climate change, addressing unsustainable agricultural practices through innovative technology and practical solutions that can be implemented now. The FuelPositive on-farm/onsite, containerized Green Ammonia production system is designed to produce pure, anhydrous ammonia for multiple applications, including fertilizer for farming, fuel for grain drying and internal combustion engines, a practical alternative for fuel cells and a solution for grid storage. Green Ammonia is also considered a key enabler of the hydrogen economy.
FuelPositive systems are designed to provide for Green Ammonia production on-farm/onsite, where and when needed. This eliminates wildly fluctuating supply chains and offers end-users clean fertilizer, energy and Green Ammonia supply security while eliminating carbon emissions from the production process. The first customers will be farmers. Farmers use 80% of the traditional grey ammonia produced today as fertilizer.
See pre-sale details here: https://fuelpositive.com/pre-sales/.
FuelPositive Corporation is based in Waterloo (Canada) and trades on the TSX Venture Exchange under the symbol NHHH and in the USA on the OTCQB under the symbol NHHHF.
For further information, please contact:
Ian Clifford
Co-Founder Chief Executive Officer and Board Chair
mailto://Ian@fuelpositive.com
Tel: 416.535.8395
https://www.fuelpositive.com
Logan Ross
Senior Vice President, Communications & Campaigns
Counsel Public Affairs, Inc.
mailto://lross@counselpa.com
Tel: 204.720.3662
https://www.counselpa.com
Investor Relations United States & International:
RB Milestone Group (RBMG)
mailto://fuelpositive@rbmilestone.com
Investor Relations Canada:
Transcend Capital Inc.
mailto://et@transcendcapitalinc.com
Cautionary Statement
Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) that are based on expectations, estimates and projections as of the date of this news release. The information in this release about future plans and objectives of the Company, including with respect to further testing and implementation of the FP300 system, are forward-looking statements.
These forward-looking statements are based on assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect.
Many of these uncertainties and contingencies can directly or indirectly affect and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Forward-looking information is provided for the purpose of providing information about management’s expectations and plans relating to the future. The Company disclaims any intention or obligation to update or revise any forward-looking information or to explain any material difference between subsequent actual events and such forward-looking information, except to the extent required by applicable law.
NEWS -- Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
KNOXVILLE, TN, April 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research by Moffitt Cancer Center (“Moffitt”) on PV-10 (rose bengal sodium) for the treatments of human papillomavirus (“HPV”)-positive and HPV-negative head and neck squamous cell carcinoma (“HNSCC”) were presented at the annual meeting of the American Association for Cancer Research (“AACR”), held April 5-10, 2024 in San Diego, California.
Titled PV-10 triggers immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma via endoplasmic reticulum stress and autophagy, a copy of Moffitt’s poster presentation is available on Provectus’s website at: https://www.provectusbio.com/media/docs/publications/AACR-poster-3-Apr-2024.pdf.
This work has been part of research conducted by Christine Chung, M.D., Chair, Department of Head and Neck-Endocrine Oncology and Program Leader of Head and Neck Oncology and members of the Chung laboratory at Moffitt in Tampa, Florida.
Moffitt observed that PV-10 induced reactive oxygen species-mediated apoptosis, surface expression of calreticulin, and extracellular ATP and HMGB1 release in HNSCC cells. PV-10-induced immunogenic cell death (“ICD”) led to surface expression of HSP-70 and HSP-90 in these cells. Intralesional (“IL”) injection of PV-10 promoted tumor regression in mice by inducing endoplasmic reticulum stress, triggering autophagy, and initiating apoptosis.
Moffitt concluded that PV-10 demonstrated significant anti-tumor activity in HNSCC. In vitro studies illustrated that PV-10 induced potent ICD in HNSCC cells, and in vivo experiments showed that IL PV-10 led to substantial tumor regression and complete responses in some mice. These findings, according to Moffitt, underscored the significance of PV-10-induced ICD, which may offer a novel and promising approach for managing HNSCC and potentially pave the way for improved survival rates and reduced adverse events.
About Provectus
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium.
Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.
Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, https://ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: The information provided in this press release may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission, including those described in Item 1A of:
The Company’s Annual Report on Form 10-K for the period ended December 31, 2023.
#####
Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
NEWS -- Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
SAN DIEGO and CALGARY, AB, April 11, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting request to the FDA. This meeting aims to discuss the Company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC).
"A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment. We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer. Our position is strengthened by encouraging data from two randomized studies (BRACELET-1 and IND-213) and the AWARE-1 study, paving the way for the next phase of pelareorep's development and its registration. Ongoing discussions with our clinical collaborators and partners have helped us to prepare a robust, compelling briefing document," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. "We eagerly anticipate our discussion with the FDA to align on the design and objectives of the registrational trial for pelareorep in metastatic breast cancer, a critical step towards bringing this innovative treatment to patients. Having a well-defined plan for the registrational track study will also help advance our strategic partnering discussions. We hope to meet with the agency in Q2 2024 and look forward to a productive dialogue. With anticipated overall survival data from the BRACELET-1 study and productive discussions with the FDA, 2024 is poised to be a transformative year for Oncolytics and our stakeholders."
Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics, added, "The data from the randomized BRACELET-1 trial showcased compelling results for the pelareorep/paclitaxel combination therapy in HR+/HER2- metastatic breast cancer patients, with a nearly tripled confirmed response rate, a 50% improvement in median progression-free survival, and a hazard ratio of 0.29 compared to the paclitaxel alone control. Importantly, these data support the statistically significant near doubling of median overall survival in another randomized phase 2 study, IND-213, which also evaluated pelareorep and paclitaxel in HR+/HER2- metastatic breast cancer patients."
Dr. Heineman continued, "Our proposed study plans to evaluate pelareorep in patients with HR+/HER2- mBC who are eligible for chemotherapy after progressing on prior hormonal therapy, including a CDK 4/6 inhibitor. We also intend to evaluate potential biomarkers, including the expansion of tumor-infiltrating lymphocytes, using T cell receptor sequencing. We look forward to the opportunity to discuss our plans with the agency and align on the best approach to advance the development of pelareorep as a potential treatment option to improve outcomes for breast cancer patients."
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in Phase 2 studies in breast and pancreatic cancers. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: https://www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our plans for a meeting with the FDA in relation to the Company's planned registration-enabling trial for pelareorep in patients with HR+/HER-2 mBC and the anticipated timing thereof; our focus in 2024; our belief that 2024 is poised to be a transformative year for Oncolytics and its stakeholders; the design and areas of evaluation for our proposed study of pelareorep in patients with HR+/HER-2 mBC; our plans to advance towards registrational studies in metastatic breast cancer and pancreatic cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to such events outside of our control, including public health crises such as pandemics and epidemics, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact
Jon Patton
Director of IR & Communication
mailto://jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
mailto://tim@lifesciadvisors.com
View original content: https://www.prnewswire.com/news-releases/oncolytics-biotech-advances-toward-registration-enabling-trial-for-pelareorep-in-breast-cancer-with-submission-of-type-c-meeting-request-to-fda-302113665.html
SOURCE Oncolytics Biotech® Inc.
NEWS -- Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Andrew Brenner, M.D., Ph.D. (Professor-Research, Departments of Medicine, Neurology, and Neurosurgery & S & B Kolitz/CTRC-Zachry Endowed Chair Neuro-Oncology Research, Mays Cancer Center at UT Health San Antonio) has formally joined the Company in a part-time capacity. Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory. In addition, Barbara Blouw, Ph.D. joins the Company as Vice President, Clinical Affairs.
“I am excited to be working more closely with the Plus team to accelerate the development of its radiopharmaceutical pipeline,” said Andrew Brenner, M.D., Ph.D. “Rhenium (186Re) obisbemeda has the potential to transform the treatment of CNS cancers, and I am pleased to be able to increase my commitment to Plus with the goal of accelerating the late-stage clinical development of the company’s existing trials in recurrent glioblastoma (GBM), leptomeningeal disease and pediatric brain cancer.”
Dr. Brenner is a board-certified internist, medical oncologist, and tumor biologist with a focus in drug development for the management of primary brain tumors and breast neoplasms. Dr. Brenner’s academic work focuses on both clinical cancer management and the development of novel therapies to treat breast and central nervous system tumors. Dr. Brenner has received numerous grants and investigational new drug approvals based on his translational research. Additionally, he has led multiple multicenter trials for the treatment of CNS neoplasms and served on Steering Committees for Phase III trials in GBM. He is a graduate of Texas A&M University and earned his doctorate in biological science and tumor biology at the University of Texas M.D. Anderson Cancer Center – Science Park. Dr. Brenner received his medical degree from the Texas Tech University Health Science Center and completed a residency at Texas A&M Health Science Center in Temple, Tx. He completed his fellowship in medical oncology at UT Health San Antonio.
Dr. Barbara Blouw has a Ph.D. from Utrecht University in the Netherlands and completed her postdoctoral research at the Sanford Burnham Prebys, Medical Discovery Institute, and the University of California, San Diego Division of Biological Sciences in basic cancer biopsy. Professionally, she has worked for Navigate Biopharma (a Novartis Company), Halozyme and Biocept. Dr. Blouw has a broad background in oncology research, clinical trial design, regulatory submissions, biostatistics, and clinical operations. She also has expertise in CNS biomarker development using in vitro and in vivo preclinical models and assay development and validations for clinical trial testing per the College of American Pathologists Laboratory Accreditation Program and Clinical Laboratory Improvement Amendments.
“As we prepare for the future, Plus is substantially strengthening its management in key areas such as cancer biology, neuro-oncologic clinical development, and central nervous system biomarker development,” said Marc H. Hedrick, M.D., M.B.A. “I have worked closely with both Dr. Brenner and Dr. Blouw for some time now, and they are important new additions for our future. Their positive impact will be felt immediately.”
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of rhenium (186Re) obisbemeda including the ability of rhenium (186Re) obisbemeda to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM and ReSPECT-PBC and increase of ten o, clinical trials; possible negative effects of rhenium (186Re) obisbemeda; the continued evaluation of rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms, and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
(212) 915-2577
mailto://cdavis@lifesciadvisors.com
NEWS -- Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the presentation of preclinical data demonstrating the potential synergy between lead product candidate, VCN-01 and liposomal irinotecan in a human pancreatic mouse xenograft. Data will be featured in a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) 27th Annual Meeting, being held both virtually and in Baltimore from May 7-11, 2024.
“We look forward to presenting data at the upcoming ASGCT meeting that further highlight the potential of our systemically administered oncolytic adenovirus, VCN-01, to synergistically combine with an expanding range of standard-of-care chemotherapies for difficult-to-treat cancers,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “ Our on-going VIRAGE Phase 2b trial is evaluating VCN-01 in combination with gemcitabine/nab-paclitaxel to treat metastatic pancreatic ductal adenocarcinoma (PDAC). The enhanced anti-tumor effects observed in the human pancreatic mouse xenograft model with VCN-01 and liposomal irinotecan provides compelling support for evaluating the combination of VCN-01 with the additional first-line pancreatic cancer chemotherapy regimens NALIRIFOX and FOLFIRINOX to provide a portfolio of improved therapeutic combinations for patients with this deadly disease.”
ASGCT Presentation Details
NEWS -- Tokens.com to Acquire AI and Robotics Business
TORONTO, April 04, 2024--(BUSINESS WIRE)--Tokens.com Corp. ("Tokens.com" or the "Company") (TSX-V: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF), a technology investment company, has entered into a share purchase agreement dated April 4, 2024 (the "Share Purchase Agreement") to acquire all of the issued and outstanding shares of Simulacra Corporation ("Simulacra" or the "Target"), a Nevada-based technology company. Simulacra owns and operates three subsidiaries focused on the integration of artificial intelligence ("AI") and high quality, humanoid robots that improve the human experience through connection, learning and play. It is expected that the transaction will close on or about April 16, 2024. All amounts herein are expressed in U.S. dollars, unless otherwise stated.
Since 1997, Simulacra has been producing realistic silicone humanoid figures. In the last four years, Simulacra has generated revenues of $15.6 million (CAD$21.1 million) and Gross Profit of $12.1 million (CAD$16.3 million). The transaction is expected to be revenue accretive to Tokens.com shareholders. More information on Simulacra can be found on their website here and an investor deck can be found here.
Utilizing its intellectual property and design expertise, Simulacra is positioned to expand beyond its current sectors of entertainment and marketing into other markets that benefit from high quality, natural looking, humanoid robots, and personalized AI systems, such as healthcare (elderly care, mental health) and education. Through their customized AI and realistic robots, Simulacra is positioned to be a leader in the newly emerging AI companionship market.
"At Tokens.com, we have been at the forefront of Web3 and blockchain technologies over the last few years. Our move into AI and robotics is a natural extension of our scope. We are excited to enter this sector with industry leaders in the AI / robotics space," said Andrew Kiguel, CEO of Tokens.com.
On the completion of the transaction, Matt McMullen, the founder and CEO of Simulacra, will join Tokens.com as President and as a director. Mr. McMullen and Shrike Holdings Inc., another Simulacra shareholder, will also become new Insiders (as defined in policies of the TSX Venture Exchange (the "TSXV")) of the Company.
"We are on the cusp of a very exciting time, as humans and technology create new ways of interacting and connecting through AI and robotics," said Mr. McMullen. "As we explore this new frontier, we are eager to share these opportunities in the public markets. This transaction with Tokens.com will greatly accelerate our strategic growth and market penetration."
"While other tech companies are building robots to replace human workers in warehouses, Simulacra’s robotics serve the more immediate use case for AI and robotics: human connection, learning and play," said Mr. Kiguel. "While most AI tools available today are filtered for content and viewpoints, Simulacra’s AI technology enables humans and robots to foster genuine connection through unfiltered, human-like conversation. We see our robots used in homes, hospitals, and even in the c-suite. We even intend on using AI to assist in board governance."
Subsequent to the completion of this transaction, Tokens.com will provide investors with exposure to: (a) blockchain, via its cryptocurrency inventory; (b) social media, Web3 gaming and the metaverse, via its 15.3% ownership interest in StoryFire; and (c) AI and Robotics, via its 100% ownership of Simulacra.
"At Tokens.com, we invest in technologies that disrupt the norm and define the future. We have broken ground in the past through investments in metaverse real estate and crypto assets such as crypto-punks and Shiba-Inu. Our goal is to continue to tap into growth via unconventional opportunities that would be overlooked by other technology companies," said Kiguel.
Transaction Consideration and Other Details
Tokens.com will issue 75 million common shares to Simulacra shareholders in consideration for the acquisition. This will equate to approximately 38% of outstanding common shares of Tokens.com on the completion of the transaction. The common shares issued to Simulacra shareholders will be escrowed for 12 months and then gradually released between months 12 to 24 following the closing date. Tokens.com will also grant an aggregate of 7,500,000 stock options in exchange for the cancellation of 567,101 stock options of Simulacra.
In addition, Simulacra shareholders will have the opportunity to earn an additional 10 million Tokens.com shares if they achieve revenue targets of $8 million within any 12 month period during the first 24 months following the completion of the transaction and an additional 10 million Tokens.com shares if they achieve revenues of $10 million with any 12 month period between months 24 and 48 following the closing date.
Subsequent to the closing of the transaction, it is expected that Tokens.com will have a total of 195,995,592 common shares outstanding and 1,469,950 in-the-money options outstanding. The Company also has 1,902,540 deferred stock units (held 100% by directors on the board) and 9,777,289 warrants outstanding with an exercise price of CAD$1.15 that expire in November 2024.
The transaction is subject to customary closing conditions, including approval from the TSXV. Each of Simulacra and its shareholders are arm’s length parties to the Company. No broker, agent or finder’s fee is payable in connection with the transaction.
Simulacra Subsidiaries
(i) Realbotix
Realbotix builds customized ultra-realistic robots that are AI-enabled. These robots look, talk, and move like humans. Invented for use in entertainment, companionship, healthcare, and education markets. For an example of Realbotix’s products, please see the link here to meet Aria, one of Realbotix’s active robots.
(ii) Anthropomorphic Figure Dynamics ("AFD")
AFD is a unique division that caters to government and healthcare projects that require highly realistic humanoids. This would include previous contracts with the US military and John Hopkins hospital.
(iii) Abyss Creations
Abyss Creations builds companionship-based humanoid figures that have the ability to be integrated with AI features. Abyss is the creator of award-winning, realistic humanoid dolls.
Completion of Strategic Review
Subsequent to the completion of this transaction, Tokens.com will have completed its strategic review (which was announced in November 2023). Highlights of the changes made since announcing the strategic review include: (1) the disposition of non-profitable, early stage businesses in a manner that still provides shareholders with upside exposure to Web3 and metaverse growth; (2) a successful move to the TSXV to enhance liquidity and profile; (3) the contemplated expansion of the business into AI and Robotics, including the proposed revenue accretive acquisition of Simulacra and its subsidiaries; and (4) the listing for sale of the Company’s domain name, Tokens.com and certain other intellectual property, with a view to rebranding the organization in a manner that captures our evolving profile and business interests.
Humanoid Robotics Market
Simulacra is focused on the convergence of AI Software and Hardware to enable humanoid robotics. The robotics sector is estimated to exceed $24 trillion in revenue annually according to ARK Investment management. Goldman Sachs predicts the humanoid robot market is anticipated to be USD $13.8 billion by 2028 and US $38 billion by 2035. The growing use of technology in education is fueling the deployment of humanoid robots in schools and driving the market's growth for the education and entertainment application segment. By blending entertainment and functionality, humanoid robots are revolutionizing how we interact and engage with technology in various sectors.
Artificial Intelligence Market
According to MarketsandMarkets, the global AI market was valued at $150.2 billion in 2023 and is expected to grow at a CAGR of 36.8% from 2023 to 2030. AI is revolutionizing multiple industries, emerging as a key driver for the advancement of technologies such as big data analytics, robotics and the Internet of Things. The rise of AI tools highlight the sector's mainstream appeal. With its current trajectory, the AI industry is poised to be a powerful tool for technological innovation, propelling advancements in the near future.
Conference Call
A call will be held on April 8, 2024 at 4:00 p.m. EST with Andrew Kiguel and Matthew McMullen to discuss the transaction and to answer questions from investors and other interested parties.
Webinar information:
Date: April 8, 2024
Time: 4:00 pm ET
Zoom Registration: https://us06web.zoom.us/webinar/register/WN_Zg7g9iTPTja6PyiJ7ZvOcg
To join the webinar, register using the link provided above. Upon registration a Zoom link will be emailed to the registered email address. The webinar will be available via computer, tablet, and smartphone devices. In addition, a dial-in phone number will be provided in the email upon registration. Callers dialing in using a telephone will automatically be placed in a listen only mode. The question period will not be available to dial-in callers.
About Tokens.com
Tokens.com is a technology investment company that focuses on disruptive businesses that are defining the future. The Company’s assets provide shareholders with exposure to AI, Blockchain, Robotics and Web3. Tokens.com also owns an inventory of cryptocurrencies and a collection of top ranked crypto related domain names.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, Facebook, Instagram and YouTube.
Forward-Looking Statements
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements in this news release include statements relating to the expected closing date of the transaction and the projected impact of the acquisition on the Company’s business, financial conditions and results.
Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. Important factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements include, among others: (a) the risk that the closing conditions for completion of the transaction, including TSXV approval, are not satisfied; (b) risks relating to general economic, market and business conditions; and (c) unforeseen delays in the timelines for any of the transactions or events described in this press release.
We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act") or any states securities laws and may not be offered or sold within the United states or to US Persons (as defined in Regulation S under the US Securities Act) unless registered under the US Securities Act and applicable state securities laws or an exemption from such registration is available.
Neither TSXV nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404204177/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Telephone: 647-578-7490
NEWS -- Tokens.com to Acquire AI and Robotics Business
TORONTO, April 04, 2024--(BUSINESS WIRE)--Tokens.com Corp. ("Tokens.com" or the "Company") (TSX-V: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF), a technology investment company, has entered into a share purchase agreement dated April 4, 2024 (the "Share Purchase Agreement") to acquire all of the issued and outstanding shares of Simulacra Corporation ("Simulacra" or the "Target"), a Nevada-based technology company. Simulacra owns and operates three subsidiaries focused on the integration of artificial intelligence ("AI") and high quality, humanoid robots that improve the human experience through connection, learning and play. It is expected that the transaction will close on or about April 16, 2024. All amounts herein are expressed in U.S. dollars, unless otherwise stated.
Since 1997, Simulacra has been producing realistic silicone humanoid figures. In the last four years, Simulacra has generated revenues of $15.6 million (CAD$21.1 million) and Gross Profit of $12.1 million (CAD$16.3 million). The transaction is expected to be revenue accretive to Tokens.com shareholders. More information on Simulacra can be found on their website here and an investor deck can be found here.
Utilizing its intellectual property and design expertise, Simulacra is positioned to expand beyond its current sectors of entertainment and marketing into other markets that benefit from high quality, natural looking, humanoid robots, and personalized AI systems, such as healthcare (elderly care, mental health) and education. Through their customized AI and realistic robots, Simulacra is positioned to be a leader in the newly emerging AI companionship market.
"At Tokens.com, we have been at the forefront of Web3 and blockchain technologies over the last few years. Our move into AI and robotics is a natural extension of our scope. We are excited to enter this sector with industry leaders in the AI / robotics space," said Andrew Kiguel, CEO of Tokens.com.
On the completion of the transaction, Matt McMullen, the founder and CEO of Simulacra, will join Tokens.com as President and as a director. Mr. McMullen and Shrike Holdings Inc., another Simulacra shareholder, will also become new Insiders (as defined in policies of the TSX Venture Exchange (the "TSXV")) of the Company.
"We are on the cusp of a very exciting time, as humans and technology create new ways of interacting and connecting through AI and robotics," said Mr. McMullen. "As we explore this new frontier, we are eager to share these opportunities in the public markets. This transaction with Tokens.com will greatly accelerate our strategic growth and market penetration."
"While other tech companies are building robots to replace human workers in warehouses, Simulacra’s robotics serve the more immediate use case for AI and robotics: human connection, learning and play," said Mr. Kiguel. "While most AI tools available today are filtered for content and viewpoints, Simulacra’s AI technology enables humans and robots to foster genuine connection through unfiltered, human-like conversation. We see our robots used in homes, hospitals, and even in the c-suite. We even intend on using AI to assist in board governance."
Subsequent to the completion of this transaction, Tokens.com will provide investors with exposure to: (a) blockchain, via its cryptocurrency inventory; (b) social media, Web3 gaming and the metaverse, via its 15.3% ownership interest in StoryFire; and (c) AI and Robotics, via its 100% ownership of Simulacra.
"At Tokens.com, we invest in technologies that disrupt the norm and define the future. We have broken ground in the past through investments in metaverse real estate and crypto assets such as crypto-punks and Shiba-Inu. Our goal is to continue to tap into growth via unconventional opportunities that would be overlooked by other technology companies," said Kiguel.
Transaction Consideration and Other Details
Tokens.com will issue 75 million common shares to Simulacra shareholders in consideration for the acquisition. This will equate to approximately 38% of outstanding common shares of Tokens.com on the completion of the transaction. The common shares issued to Simulacra shareholders will be escrowed for 12 months and then gradually released between months 12 to 24 following the closing date. Tokens.com will also grant an aggregate of 7,500,000 stock options in exchange for the cancellation of 567,101 stock options of Simulacra.
In addition, Simulacra shareholders will have the opportunity to earn an additional 10 million Tokens.com shares if they achieve revenue targets of $8 million within any 12 month period during the first 24 months following the completion of the transaction and an additional 10 million Tokens.com shares if they achieve revenues of $10 million with any 12 month period between months 24 and 48 following the closing date.
Subsequent to the closing of the transaction, it is expected that Tokens.com will have a total of 195,995,592 common shares outstanding and 1,469,950 in-the-money options outstanding. The Company also has 1,902,540 deferred stock units (held 100% by directors on the board) and 9,777,289 warrants outstanding with an exercise price of CAD$1.15 that expire in November 2024.
The transaction is subject to customary closing conditions, including approval from the TSXV. Each of Simulacra and its shareholders are arm’s length parties to the Company. No broker, agent or finder’s fee is payable in connection with the transaction.
Simulacra Subsidiaries
(i) Realbotix
Realbotix builds customized ultra-realistic robots that are AI-enabled. These robots look, talk, and move like humans. Invented for use in entertainment, companionship, healthcare, and education markets. For an example of Realbotix’s products, please see the link here to meet Aria, one of Realbotix’s active robots.
(ii) Anthropomorphic Figure Dynamics ("AFD")
AFD is a unique division that caters to government and healthcare projects that require highly realistic humanoids. This would include previous contracts with the US military and John Hopkins hospital.
(iii) Abyss Creations
Abyss Creations builds companionship-based humanoid figures that have the ability to be integrated with AI features. Abyss is the creator of award-winning, realistic humanoid dolls.
Completion of Strategic Review
Subsequent to the completion of this transaction, Tokens.com will have completed its strategic review (which was announced in November 2023). Highlights of the changes made since announcing the strategic review include: (1) the disposition of non-profitable, early stage businesses in a manner that still provides shareholders with upside exposure to Web3 and metaverse growth; (2) a successful move to the TSXV to enhance liquidity and profile; (3) the contemplated expansion of the business into AI and Robotics, including the proposed revenue accretive acquisition of Simulacra and its subsidiaries; and (4) the listing for sale of the Company’s domain name, Tokens.com and certain other intellectual property, with a view to rebranding the organization in a manner that captures our evolving profile and business interests.
Humanoid Robotics Market
Simulacra is focused on the convergence of AI Software and Hardware to enable humanoid robotics. The robotics sector is estimated to exceed $24 trillion in revenue annually according to ARK Investment management. Goldman Sachs predicts the humanoid robot market is anticipated to be USD $13.8 billion by 2028 and US $38 billion by 2035. The growing use of technology in education is fueling the deployment of humanoid robots in schools and driving the market's growth for the education and entertainment application segment. By blending entertainment and functionality, humanoid robots are revolutionizing how we interact and engage with technology in various sectors.
Artificial Intelligence Market
According to MarketsandMarkets, the global AI market was valued at $150.2 billion in 2023 and is expected to grow at a CAGR of 36.8% from 2023 to 2030. AI is revolutionizing multiple industries, emerging as a key driver for the advancement of technologies such as big data analytics, robotics and the Internet of Things. The rise of AI tools highlight the sector's mainstream appeal. With its current trajectory, the AI industry is poised to be a powerful tool for technological innovation, propelling advancements in the near future.
Conference Call
A call will be held on April 8, 2024 at 4:00 p.m. EST with Andrew Kiguel and Matthew McMullen to discuss the transaction and to answer questions from investors and other interested parties.
Webinar information:
Date: April 8, 2024
Time: 4:00 pm ET
Zoom Registration: https://us06web.zoom.us/webinar/register/WN_Zg7g9iTPTja6PyiJ7ZvOcg
To join the webinar, register using the link provided above. Upon registration a Zoom link will be emailed to the registered email address. The webinar will be available via computer, tablet, and smartphone devices. In addition, a dial-in phone number will be provided in the email upon registration. Callers dialing in using a telephone will automatically be placed in a listen only mode. The question period will not be available to dial-in callers.
About Tokens.com
Tokens.com is a technology investment company that focuses on disruptive businesses that are defining the future. The Company’s assets provide shareholders with exposure to AI, Blockchain, Robotics and Web3. Tokens.com also owns an inventory of cryptocurrencies and a collection of top ranked crypto related domain names.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, Facebook, Instagram and YouTube.
Forward-Looking Statements
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements in this news release include statements relating to the expected closing date of the transaction and the projected impact of the acquisition on the Company’s business, financial conditions and results.
Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. Important factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements include, among others: (a) the risk that the closing conditions for completion of the transaction, including TSXV approval, are not satisfied; (b) risks relating to general economic, market and business conditions; and (c) unforeseen delays in the timelines for any of the transactions or events described in this press release.
We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act") or any states securities laws and may not be offered or sold within the United states or to US Persons (as defined in Regulation S under the US Securities Act) unless registered under the US Securities Act and applicable state securities laws or an exemption from such registration is available.
Neither TSXV nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404204177/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Telephone: 647-578-7490
NEWS -- FuelPositive Welcomes Deputy Minister of Agriculture and Agri-Food Canada to Facility in Waterloo and Announces Non-Brokered Private Placement
WATERLOO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- FuelPositive Corporation, a leading Green Ammonia Company (TSX.V: NHHH) (OTCQB: NHHHF) (the "Company" or "FuelPositive") is pleased to announce it had the honour to welcome the Federal Deputy-Minister of Agriculture and Agri-Food Canada, Stefanie Beck, for a tour of its new facility in Waterloo Canada. This second visit from the Federal Ministry of Agriculture underscored the importance of FuelPositive's work, as it closely followed the highly positive visit of the Honorable Minister of Agriculture, Lawrence MacAulay.
During the tour and subsequent round table discussion, FuelPositive's team showcased its cutting-edge systems and upgraded facilities, providing insight into its transformative approach to lowering both the cost and GHG intensity of fertilizers and fuel.
"Deputy Minister Beck recently visited our team at our new facility during her visit to the Kitchener-Waterloo region. Our team offered her a warm reception and discussed the Company's clean technology solutions, including the production of Green Ammonia and its advantages for on-farm fertilizer and fuel use," stated Ian Clifford FuelPositive CEO and Board Chair.
Deputy Minister Beck was joined by Alec Nicholls, Director General, Agriculture and Agri-Food Canada, Melissa Reginato, Senior Markets and Trade, Agriculture and Agri-Food Canada and Hadley Carpenter, Regional Director, Agriculture and Agri-Food Canada, who was instrumental in organizing the visit.
"FuelPositive has the potential to transform Canada's green fertilizer and sustainable fuel sectors. Our technology embodies the spirit of progress and collaboration and showcases Canada's leadership in pioneering solutions that address pressing global challenges. We hope that we effectively communicated the urgency for the government to continue to support projects like ours, destined to improve farmers' quality of life," stated Luna Clifford, FuelPositive Chief impact Officer.
The governmental visit was a valuable opportunity for the FuelPositive team to engage in meaningful discussions with Deputy Minister Beck. The team addressed vital issues surrounding the resilience of rural communities and the challenges farmers face in today's evolving landscape. The team emphasized the importance of addressing the lack of predictability in farming, exacerbated by climate change, fertilizer shortages, and profound supply chain cost fluctuations.
FuelPositive's team highlighted how its technology stands apart from traditional fertilizer production methods in its superior environmental impact mitigation. Unlike organic fertilizers derived from animal agriculture or traditional synthetic fertilizers reliant on fossil fuels, both posing significant ecological and social challenges, FuelPositive’s Green Ammonia fertilizer is produced without utilizing animals or fossil fuels, offering many advantages over these current unsustainable ways of producing fertilizer.
FuelPositive's innovative approach not only distinguishes the Company in the market but also equips Canadian farmers with a long-term, reliable solution to enhance productivity and optimize resources, all while minimizing environmental harm.
As advocates for the agricultural community, FuelPositive eagerly awaits further dialogue and collaboration with the Canadian Government and its agencies to drive positive change. "As we embark on this exciting journey, collaborating with government entities holds immense potential to empower our farmers, address hidden challenges, and enhance the resilience of rural communities. Together, we forge a path towards sustainable agriculture, driving positive change and securing a brighter future for all stakeholders," stated Ian Clifford, FuelPositive CEO and Board Chair. "Thank you to the Federal Ministry of Agriculture for acknowledging our work and taking the time to understand how a decentralized, on-farm approach to fertilizer and fuel production can directly contribute to Canadian farmers meeting their greenhouse gas emissions mitigation targets. Having access to fertilizer as needed has a positive impact on optimizing farmers' yield and offers stability and security, both economically and socially. Decentralization is key for sustainable change," concluded Ian Clifford.
A pivotal moment during the Deputy Minister's visit was when Dr. Leith Deacon, FuelPositive's Rural Planning and Development Advisor, also provided his insight during the meeting. Dr. Deacon shared vital statistics with the Deputy Minister and her team, underscoring the urgent need for government leadership to ensure a viable future for rural and farming communities. "Leith's role within FuelPositive has been key in helping educate the team about what matters most to farmers: their priorities, immediate need for support, and challenges," stated Luna Clifford, FuelPositive's Chief Impact Officer.
A professor in the School of Environmental Design and Rural Development in the Ontario Agriculture College at the University of Guelph, Dr Deacon is also a registered professional planner (RPP) and holds membership with the Canadian Institute of Planners (MCIP). His research focuses on governance, resiliency, mental health, planning, and policy primarily related to small, agricultural, and rural communities. Dr Deacon is the lead investigator of the Sustainable Community Planning Development Project https://www.sustainablecommunityplanning.com, with a goal to contribute knowledge to the field of rural planning and developing by examining the concept of resilience within small, agricultural, and rural communities. He has been an invaluable guide in FuelPositive's journey to understand the reality of farmers and rural communities today.
During the Deputy Minister Becks visit, Dr. Deacon emphasized the importance of mindful and targeted interventions to address the pressing challenges farmers face today, stating: "FuelPositive is working to give autonomy and control to farmers with their onsite, containerized, Green Ammonia production system. This system revolutionizes how farmers access fertilizers and, critically, offers much-needed long-term price predictability. Economic uncertainty is a leading contributor to poor mental health and increased anxiety in rural communities, both of which are directly linked to the high rates of suicide within Canada's farming communities. The FuelPositive system can potentially help reduce anxiety associated with cost predictability and support the long-term resilience of Canada's farmers."
Resilience manifests in various forms within a community's fabric. Social resilience speaks to the community's ability to support its members' well-being and inclusivity. Economic resilience focuses on adaptability amid unforeseen events, ensuring stability at individual and community levels. Environmental resilience centers on the community's capacity to absorb environmental changes with ease. Legislative/governance resilience encompasses long-term strategies that promote good governance, stability, and diversity through inclusive policies and transparent approaches. Together, these facets bolster a community's ability to navigate challenges and thrive despite adversity.
FuelPositive’s team is proud to be addressing all facets of resiliency and count on the governments of Canada, at all levels, to develop supportive legislative incentives and programs. "The decentralization of energy, fertilizer and fuel production is at the core of FuelPositive's innovative technology and should also be at the core of the Canadian transition toward a more resilient agriculture sector," concluded Luna Clifford.
Non-Brokered Private Placement
The Company is pleased to announce that it will offer (the “Offering”) up to 54,545,455 units (each, a “Unit”) by way of non-brokered private placement at a price of $0.055 per Unit for aggregate gross proceeds of up to $3,000,000. Each Unit will consist of one common share of the Company and one common share purchase warrant allowing holders to purchase an additional common share at a price of $0.07 for a period of sixty months.
The net proceeds from the Offering will be utilized for general working capital purposes with a focus on accelerating its various initiatives in the Province of Manitoba. In connection with completion of the Offering, the Company may pay finders’ fees to eligible third parties who have assisted in introducing subscribers to the Company.
In connection with completion of the Offering, the Company also intends to settle (the “Debt Settlement”) outstanding indebtedness of $56,000 owing to certain arms-length credits in consideration for the issuance of 1,018,182 Units at a deemed price of $0.055 per Unit.
All securities issued in connection with the Offering and Debt Settlement will be subject to a statutory hold period of four-months-and-one-day in accordance with applicable securities laws. Completion of the Offering and the Debt Settlement remain subject to the approval of the TSX Venture Exchange.
About FuelPositive Corporation
FuelPositive is a Canadian technology company dedicated to delivering commercially feasible and sustainable clean technology solutions that follow a circular approach, ensuring the entire lifecycle of our products is environmentally friendly. This includes an on-farm/onsite, containerized Green Ammonia (NH3) production system that effectively eliminates carbon emissions during the production process.
By focusing on clean, sustainable, economically advantageous and realizable technologies, the Company aims to help mitigate climate change, addressing unsustainable agricultural practices through innovative technology and practical solutions that can be implemented now. The FuelPositive on-farm/onsite, containerized Green Ammonia production system is designed to produce pure, anhydrous ammonia for multiple applications, including fertilizer for farming, fuel for grain drying and internal combustion engines, a practical alternative for fuel cells and a solution for grid storage. Green Ammonia is also considered a key enabler of the hydrogen economy.
FuelPositive systems are designed to provide for Green Ammonia production on-farm/onsite, where and when needed. This eliminates wildly fluctuating supply chains and offers end-users clean fertilizer, energy and Green Ammonia supply security while eliminating carbon emissions from production. The first customers will be farmers. Farmers use 80% of the traditional grey ammonia produced today as fertilizer.
Sales details here: https://fuelpositive.com/sales/
FuelPositive Corporation is based in Waterloo (Canada) and trades on the TSX Venture Exchange under the symbol NHHH and on the OTCQB under the symbol NHHHF in the USA.
For further information, please contact:
Ian Clifford
Chief Executive Officer and Board Chair
mailto://Ian@fuelpositive.com
Tel: 416.535.8395
https://www.fuelpositive.com
Logan Ross
Senior Vice President, Communications & Campaigns
Counsel Public Affairs, Inc.
mailto://lross@counselpa.com
Tel: 204.720.3662
https://www.counselpa.com
Investor Relations United States & International:
RB Milestone Group (RBMG)
mailto://fuelpositive@rbmilestone.com
Investor Relations Canada:
Transcend Capital
et@transcendcapitalinc.com
Cautionary Statement
Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") that are based on expectations, estimates and projections as of the date of this news release. The information in this release about future plans and objectives of the Company, including with respect to further testing and implementation of the FP300 system, are forward-looking statements.
These forward-looking statements are based on assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect.
Many of these uncertainties and contingencies can directly or indirectly affect and could cause actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Forward-looking information is provided for the purpose of providing information about management's expectations and plans relating to the future. The Company disclaims any intention or obligation to update or revise any forward-looking information or to explain any material difference between subsequent actual events and such forward-looking information, except to the extent required by applicable law.
NEWS -- FuelPositive Participates in NICCEE’s Green Ammonia Event in the USA
WATERLOO, Ontario, April 03, 2024 (GLOBE NEWSWIRE) -- FuelPositive Corporation, a leading Green Ammonia Company (TSX.V: NHHH) (OTCQB: NHHHF) (the "Company" or "FuelPositive") is pleased to announce that on March 15, 2024, the United States National Science Foundation funded Global Nitrogen Innovation Center for Clean Energy and the Environment (NICCEE) held an exploratory meeting with regional agricultural partners in the Chesapeake Bay Watershed's key grain production region, the Eastern Shore of Maryland.
FuelPositive was invited by Dr. Matthew Houser, a Senior Social Scientist at The Nature Conservancy and Assistant Research Professor at the University of Maryland Center for Environmental Science, to present their breakthrough Green Ammonia story.
The Global Nitrogen Innovation Center for Clean Energy and the Environment (NICCEE), spearheaded by the University of Maryland Center for Environmental Science (UMCES) with key partners in the U.S. (New York University and iUniversity of Massachusetts Amherst), Canada (University of Guelph), and the U.K. (Rothamsted Research), provide timely and crucial insights associated with the rapidly evolving technological innovation to produce Green Ammonia using renewable energy for clean energy and food production.
The meeting's goal was to inform potential end-users about the emerging on-farm green ammonia production technology and document their perceived opportunities and concerns related to adoption.
The meeting attendees represented various parties involved in agricultural nitrogen management, including grain farmers, regional fertilizer distributors, agricultural policy representatives, and agricultural conservation organizations. "In addition to several presentations that covered the purpose of NICCEE and the overall development of Green Ammonia, FuelPositive CEO Ian Clifford joined to discuss the Company's On-farm Green Ammonia units. During a facilitated discussion, workshop participants offered their perspectives on this new technology, centered around FuelPositive's system." stated Dr Houser.
"Regional distributors and farmers alike are "price takers" when it comes to inputs that FuelPositive's system can produce or replace, such as nitrogen fertilizer and propane for grain drying. Both groups were primarily excited about the potential to "take control" of these inputs, which would enable retailers to offer customers' better nitrogen prices and farmers to have consistent input costs. They like the independence it gives them: the stability and predictability of the price and supply. While farmers and distributor participants noted some potential adoption and implementation challenges, there was general enthusiasm about the economic and environmental potential of these systems and several participants expressed that they were seriously considering these units for their operation," continued Dr Houser.
"We feel deeply honoured to have been invited to meet such open-minded farmers and leaders in the Green Ammonia sector. Participating in a full day of discussion and debate with individuals who share a commitment to environmental responsibility in agriculture was truly inspiring. Our ongoing and increasing encounters with passionate advocates committed to optimizing agriculture while safeguarding the environment have been remarkable. It reaffirms our collective dedication to fostering sustainable practices to benefit our planet and future generations," concluded Ian Clifford, FuelPositive CEO and Board Chair.
NICCEE plans to host future partner workshops in other regions across the US, Canada, and the UK to assess how perceptions differ across and within national boundaries. As an Innovation Partner of NICCEE, FuelPositive will benefit from this wealth of information about a newly emerging sector and its first end-users.
About FuelPositive Corporation
FuelPositive is a Canadian technology company dedicated to delivering commercially feasible and sustainable clean technology solutions that follow a circular approach, ensuring the entire lifecycle of our products is environmentally friendly. This includes an on-farm/onsite, containerized Green Ammonia (NH3) production system that effectively eliminates carbon emissions during the production process.
By focusing on clean, sustainable, economically advantageous and realizable technologies, the Company aims to help mitigate climate change, addressing unsustainable agricultural practices through innovative technology and practical solutions that can be implemented now. The FuelPositive on-farm/onsite, containerized Green Ammonia production system is designed to produce pure, anhydrous ammonia for multiple applications, including fertilizer for farming, fuel for grain drying and internal combustion engines, a practical alternative for fuel cells and a solution for grid storage. Green Ammonia is also considered a key enabler of the hydrogen economy.
FuelPositive systems are designed to provide for Green Ammonia production on-farm/onsite, where and when needed. This eliminates wildly fluctuating supply chains and offers end-users clean fertilizer, energy and Green Ammonia supply security while eliminating carbon emissions from production. The first customers will be farmers. Farmers use 80% of the traditional grey ammonia produced today as fertilizer.
Sales details here: https://fuelpositive.com/sales/
FuelPositive Corporation is based in Waterloo (Canada) and trades on the TSX Venture Exchange under the symbol NHHH and on the OTCQB under the symbol NHHHF in the USA.
For further information, please contact:
Ian Clifford
Chief Executive Officer and Board Chair
mailto://Ian@fuelpositive.com
Tel: 416.535.8395
https://www.fuelpositive.com
Logan Ross
Senior Vice President, Communications & Campaigns
Counsel Public Affairs, Inc.
mailto://lross@counselpa.com
Tel: 204.720.3662
https://www.counselpa.com
Investor Relations United States & International:
RB Milestone Group (RBMG)
mailto://fuelpositive@rbmilestone.com
Investor Relations Canada:
Transcend Capital
mailto://et@transcendcapitalinc.com
Cautionary Statement
Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") that are based on expectations, estimates and projections as of the date of this news release. The information in this release about future plans and objectives of the Company, including with respect to further testing and implementation of the FP300 system, are forward-looking statements.
These forward-looking statements are based on assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect.
Many of these uncertainties and contingencies can directly or indirectly affect and could cause actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Forward-looking information is provided for the purpose of providing information about management's expectations and plans relating to the future. The Company disclaims any intention or obligation to update or revise any forward-looking information or to explain any material difference between subsequent actual events and such forward-looking information, except to the extent required by applicable law.